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EFFECTS OF HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I MOLECULE
COMPONENTS ON PANCREATIC CANCER CELL MIGRATION

Bailee Helena Lamberty Sliker, Ph.D.
University of Nebraska, 2019

Supervisor: Joyce C. Solheim, Ph.D.
Human leukocyte antigen (HLA) class I molecules are composed of a light chain
(beta 2-microglobulin (β2m)) and HLA heavy chain. The heavy chains of these
molecules have three different isotypes (–A, -B, and –C) and are highly polymorphic with
thousands of sequence variations termed allotypes. The best-known role for these
molecules is within the immune system, however, recent research implicates
components of this molecule can function outside of this known immune role by
contributing to cell migration. However, no studies have been published thus far
investigating this non-immune function in pancreatic cancer. Therefore, I examined the
role of HLA class I molecule components in pancreatic cancer cell migration.
My studies showed that when β2m was knocked down using β2m-specific siRNA,
cell migration decreased in the S2-013 and PANC-1 cells but increased in the MIA
PaCa-2 cells. Interactions with amyloid precursor-like protein 2 (APLP2) as well as total
APLP2 protein expression are potential mediators of these effects. HLA-B knockdown
using HLA-B-specific siRNA increased cell migration in S2-013 cells, while in both the
PANC-1 and MIA PaCa-2 cells knockdown decreased migration. Alterations in integrin
beta 1 (ITGB1) and focal adhesion kinase (FAK) are potential intermediates in HLA-B’s
effects on cell migration. Furthermore, knockdown using allotype-specific siRNA of HLAA24 in the S2-013 cell line and HLA-A2 in PANC-1 cell line increased migration while
knockdown of HLA-A2 in the S2-013 cell line and HLA-A24 in the MIA PaCa-2 cell line
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reduced cell migration. Mechanistically, APLP2 C-terminal fragment (APLP2-CT) and
epidermal growth factor receptor (EGFR) are likely mediators of this phenotype. Finally,
the histone deacetylase (HDAC) inhibitor M344 and its effects on APLP2 processing in
the S2-013 pancreatic cancer cell line was interrogated as previous studies indicated
M344 treatment reduced levels of β-site APP cleaving enzyme 1 (BACE1), a proteolytic
enzyme involved in APLP2 cleavage. M344 treatment of S2-013 cells led to a significant
reduction in cell proliferation, migration, and APLP2-CT expression. Overall, this work
sheds light on a novel role for the HLA class I molecules in pancreatic cancer outside of
their known immune function and implicates M344 as a potential new therapeutic for this
lethal disease.
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CHAPTER 1: Introduction to the human leukocyte antigen (HLA) class I molecule

2
1.1 HLA class I molecule structure

The major histocompatibility complex (MHC) class I molecule in its human form is
also termed the HLA class I molecule. The HLA class I molecule is present on nearly all
nucleated cells and is composed of three main components (Figure 1.1). The first is the
heavy alpha (α) chain (encoded on human chromosome 6) and the second is the small
soluble beta 2-microglobulin (β2m) that is denoted as the light chain of this structure and
is encoded on chromosome 15. The final component is the peptide that is being
presented, which sits in the peptide groove of the heavy chain.
The HLA class I alpha chain is composed of an α1 and α2 domain that form the
peptide binding cleft as well as an α3 domain, transmembrane helix, and cytoplasmic
domain. β2m, which is highly conserved in all vertebrates, is non-covalently attached to
the HLA class I heavy chain. The HLA class I molecule heavy chain is known for its
highly polymorphic nature and there are three main heavy chain isotypes that occur in
the human population which include HLA-A, HLA-B, and HLA-C. Due to the high
number of polymorphisms of these molecules, there are thousands of different
possibilities for these molecules termed allotypes that include the specific sequences
present in each individual (Table 1.1). Examples of allotypes include HLA-A2, HLA-A24,
HLA-B7, and HLA-B27. Further still, sequencing has found that there are even further
variations of these allotypes and these numbers can be taken out to four digits to further
differentiate the variations within this molecule. Each individual inherits up to 6 different
heavy chain alleles from their parents (usually 3 alleles from each parent) and this is
termed a haplotype. β2m, on the other hand, does not share this high rate of
polymorphism, and there is only one human β2m allele. These three aforementioned
heavy chain isotypes and their accompanying variations are termed the classical MHC
molecules while there are also non-classical forms of this molecule, which include HLA-

3
Figure 1.1. Components of the HLA class I molecule. Present on all nucleated cells,
HLA class I molecules are composed of a heavy chain that has α1, α2, and α3 domains
indicated in blue, transmembrane/cytoplasmic domains shown in black, a light chain
(β2m) indicated in green, and endogenous antigenic peptide indicated in orange.
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Figure 1.1.
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Table 1.1. Table of the number of unique sequences for the HLA class I heavy chain
isotypes present in the human population.

Data taken from IPD-IMGT/HLA.
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Table 1.1.
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G and HLA-E among others. For the purposes of this dissertation, we will be focusing
on the classical MHC molecules (Peaper and Cresswell 2008).

1.2 HLA class I molecule and its immune system function

One of the main functions of the HLA class I molecule is its role in the adaptive
immune system where it presents endogenous peptides to cytotoxic T cells. It does this
with the help of the peptide-loading complex (PLC), which performs the general function
of loading peptide onto the HLA class I molecule. The PLC also functions to perform
quality control on the newly assembled HLA-peptide complexes. Peptides derived from
intracellular sources are degraded by the cytosolic proteasome-ubiquitin system and are
transported into the endoplasmic reticulum (ER) lumen by the transporter associated
with antigen-processing (TAP) protein. Once the peptides are in the lumen of the ER,
they are trimmed to a length of 8 or 9 amino acids in length by aminopeptidases. Newly
formed HLA heavy chains first bind to calnexin until they begin to fold and associate with
β2m. The chaperones tapasin, calreticulin, and ERp57 work to stabilize the nascent HLA
protein and this allows for proper loading of peptide into the HLA peptide binding groove
as well as for association with β2m. Once the peptide has been loaded, the complex is
released and shuttled through the Golgi to the cell surface for peptide presentation. Any
disruption in any of these PLC components leads to inefficient peptide presentation by
HLA class I molecules. Any misfolding that occurs with the HLA class I molecule also
leads to their retention in the ER until correct folding or degradation can occur (Peaper
and Cresswell 2008). Of note, it has not been fully elucidated how the HLA class I
molecules traffic to the cell surface but a few theories exist regarding how this happens
(Figure 1.2) (Hulpke and Tempe 2013; Springer 2015).

8
Figure 1.2. Overall schematic of peptide presentation pipeline for the HLA class I
molecule. Generally, peptides are degraded by the proteasome and loaded onto the
HLA class I molecule. After peptide is loaded into the peptide-binding groove, the HLA
class I molecule is shuttled to the cell surface for peptide presentation to the immune
system.

Figure from:
Hulpke S, Tampe R. The MHC I loading complex: a multitasking machinery in adaptive
immunity. Trends in biochemical sciences. 2013; 38(8):412-420.
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Figure 1.2.
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The best-studied function for the HLA class I molecules is their role within the
immune system in which they allow cytotoxic T cells to eradicate cells that are harboring
foreign, mutated, or even in some cases overexpressed, proteins. These molecules
allow T cells to monitor the inside of cells and to lyse virally infected cells or cancer cells
by displaying fragments of representative proteins from within the cell. When a T cell
finds a peptide that it does not recognize located within the peptide groove of these
molecules, it lyses this target cell (Figure 1.3 and 1.4). Peptides that bind the groove of
the particular MHC class I heavy chain are bound both at the C-terminal and N-terminal
ends with key anchor residues also present at a few locations in the sequence. The
highly polymorphic nature of HLA class I molecules affects the peptide binding groove
leading to enhancement of the peptide repertoire that can be presented. This supports
each heavy chain allotype having the ability to bind to a different array of peptides and
leads to the maximization of the number of antigenic peptides that individuals can
present (Wieczorek et al., 2017).
HLA class I molecules are also ligands for natural killer (NK) cells and are
recognized by their killer cell immunoglobulin-like receptors (KIR) as well as other
leukocyte immunoglobulin-like receptors (LILR). These receptors are also highly
polymorphic, therefore, they recognize specific HLA class I molecules. Specifically,
KIRs recognize specific α1 and α2 domains, whereas LILRs have much broader
specificity due to their recognition of β2m and α3 (Li and Raghaven 2010). Thus, by their
interactions with NK cell receptors, as well as by their interactions with T cell receptors,
HLA class I molecules have vital functions in immunity.

1.3 The HLA class I light chain (β2m)
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Figure 1.3. Structural diagram of peptide loaded into the peptide-binding groove of the
HLA class I molecule. Diagram of the HLA-A2 molecule (α1, α2, and α3 domains of the
heavy chain indicated by blue ribbons and β2m shown in cyan ribbons) with peptide (red)
in the peptide-binding groove. Green and yellow ribbons are indicative of the variable
domains of the antigen-specific T cell receptor (TCR).

Figure from:
Flutter B, Gao B. MHC class I antigen presentation-recently trimmed and well presented.
Cellular and Molecular Immunology. 2004; 1(1):22-30.
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Figure 1.3.
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Figure 1.4. HLA class I molecules present peptide to cytotoxic CD8+ T cells. HLA class
I molecules are best known for their role within the immune system where they present
endogenous peptides to CD8+ T cells. Recognition of peptide by the T cell then leads to
lysis of the target cell. This function is used as a mechanism for protection against viral
infection and malignant transformation.

Figure from:
Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour
immunity. Nat Rev Cancer. 2004;4(1):36-44.
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Figure 1.4.
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β2m, the non-glycosylated invariant light chain of the HLA class I molecule, has
no known variants in humans (Bjorkman and Parham 1990; Townsend et al., 1989).
This protein is highly conserved among vertebrate organisms with human and mouse
β2m sharing 70% sequence similarity (Cox et al., 1982). There is no transmembrane
region of this protein and it is non-covalently bound to the α chain of the HLA class I
molecule, therefore, it is able to be exchanged with free β2m in bodily fluids such as
serum and blood (Bjorkman et al., 1987; Hyafil and Strominger 1979; Parker and
Strominger 1985). Additionally, this protein is also present in urine and is processed
through the kidneys (Karlsson et al, 1980). The β2m protein has two tryptophans that
are crucial for its function, including Trp60 which helps bind to the HLA class I molecule
and Trp95 which contributes to protein stability (Esposito et al., 2008; Ricagno et al.,
2008; Valleix et al., 2012).
β2m-deficient mice are viable and are not sterile, however, they do exhibit some
immune system dysfunctions. It has been found with deletion of β2m that there is a
degradation and subsequent low expression of misfolded HLA class I molecules,
especially at the cell surface, due to the retention of the heavy chains in the endoplasmic
reticulum. The association of β2m with the class I heavy chain occurs very early during
folding, thus the absence of β2m precludes all of the folding and assembly steps,
contributing to the lack of HLA class I expression that is observed when β2m is deleted
or mutated (Hoglund et al., 1998). Therefore, cells lacking β2m express very low levels
of HLA class I complexes on their surface, which impedes cellular immune response (Bix
and Raulet 1992). Furthermore, β2m-knockout mice have been found to have severely
impaired CD8-positive T cell immunity; however, they are still able to generate CD4positive T cell activity (Zijlstra et al., 1990). Additionally, NK cell number is normal but
NK cells have impaired functions in these mice (Ardeniz et al., 2015). In a study of
patients with low β2m expression, it was found that those with heterozygous expression
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do not experience as severe a phenotype as those with a homozygous mutation/deletion
(Ardeniz et al., 2015). Conversely, when β2m is overexpressed, there is an inhibition of
the yield of monocyte-derived dendritic cells (MoDCs) and alterations in the cytokine
secretion profiles of DCs, as well as compromised capacity of MoDCs to present
antigens to activated T cells (Xie et al., 2003).
β2m also non-covalently interacts with other molecules besides the HLA class I
molecule and this includes many of the non-classical MHC class I molecules such as
cluster of differentiation 1 (CD1), neonatal Fc receptor (FcRn), and hemostatic iron
regulator (HFE), among others (Li et al., 2016). This interaction of β2m with the nonclassical MHC class I molecules leads to more problems for humans that lack this
protein as compared to those that have loss of HLA class I molecules alone (Ardeniz et
al., 2015). These additional issues include iron overload (due to unstable HFE protein)
as well as increased catabolism of IgG and albumin due to the low expression of the
FcRn (Figure 1.5) (Christianson et al., 1997; Ehrlich and Lemonnier 2000; Enns 2001;
Schaible et al., 2002).

1.4 HLA class I components in cancer

1.4.1 β2m and cancer
Studies investigating the role of β2m in the phenotypes of cancer cells have used
models of breast cancer, oral squamous cell carcinoma, renal cell carcinoma, colon
cancer, prostate cancer, ovarian cancer, gastric cancers, and esophageal cancer, as
well as multiple subsets of leukemia and lymphoma (Bossard et al., 2012; Chen et al.,
2008; Cooper and Plesner 1980; Huang et al., 2006; Josson et al., 2011; Li et al., 2014;
Molica et al., 1999; Nomura et al., 2006; Tanaka et al., 2012). Overall, in these
particular types of tumors, high expression of β2m in the cancer cells is generally

17
Figure 1.5. β2m is the light chain for classical HLA class I molecules as well as other
non-classical MHC molecules. β2m (indicated in yellow) has been found to interact not
only with the classical HLA class I molecules (HLA-A, -B, and –C) but also some of the
non-classical HLA molecules as well. This can cause additional defects that are
observed in β2m knockout mice.
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Figure 1.5.
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correlated with worse survival for these patients, although its effects have been found to
be cell type specific. In addition to expression data, functional studies have also been
performed to investigate how β2m contributes to disease progression. It was found that
β2m plays a role in promoting cell migration and proliferation, and in preventing
apoptosis, and that loss of this protein by experimental mechanisms leads to a reduction
in these processes. This phenotype holds true both in vitro and in vivo. Mechanistically,
these effects were caused by various pathways dependent on cancer cell type (Bossard
et al., 2012; Chen et al., 2008; Cooper and Plesner 1980; Huang et al., 2006; Josson et
al., 2011; Li et al., 2014; Molica et al., 1999; Nomura et al., 2006; Tanaka et al., 2012).
In prostate cancer and renal cell carcinoma, it was found that β2m causes an
upregulation of p-PKA and p-CREB leading to VEGF production (Josson et al., 2011;
Nomura et al., 2006). Additionally, epithelial-mesencymal transition (EMT) markers are
upregulated in these models, and induction of the ERK and Akt pathways has also been
noted as being upregulated in cells with overexpression of β2m (Josson et al., 2011).
Furthermore, in ovarian cancer models, the effects of β2m were found to be correlated
with the TGF-β signaling pathway (Figure 1.6) (Sun et al., 2016).
Similarly, the serum of cancer patients has been studied for the presence of β2m.
It has been found that patients with pancreatic cancer, breast cancer, kidney cancer,
prostate cancer, and various types of leukemia and lymphoma have high expression of
β2m in their serum and β2m has been suggested as a potential biomarker for these
diseases (Gross et al., 2007; Gulec et al., 2012; Hogdall et al., 2010; Lucarelli et al.,
2014; Petekkaya et al., 2014; Petekkaya et al., 2017; Pezelli et al., 1995; Prizment et al.,
2016; Rashid et al., 1980). However, as the literature stands now, there are no
functional or mechanistic studies that have further investigated how β2m present in the
serum of patients might have any disease significance.
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Figure 1.6. β2m has been implicated in many signaling pathways important to cancer.
β2m has been found to play a role in many different pathways in various cancers. Many
of the pathways in which it is implicated lead to increased cell proliferation and migration
with a reduction in apoptosis as β2m generally leads to cancer progression. Red arrows
indicate a decrease in the expression of downstream signaling molecules by β2m.
Green arrows indicate an increase in the expression of downstream signaling molecules
by β2m. Blue arrows indicate the functional phenotypes that are altered as a results of
changes due to β2m expression or antibody binding.
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1.4.2 HLA class I heavy chains and cancer
Many studies have been done looking at the role that HLA class I molecules play
in cancer, specifically in regards to their function within the immune system and the
immune escape of various types of cancers. In a large variety of cancers, it has been
found that total HLA class I expression is reduced at the cell surface to protect cells from
CD8+ T cell recognition and subsequent lysis. Many studies have indicated that high
expression of HLA class I molecules in this context leads to improved survival, due to
functionality of the immune system in removing cancer cells (Garrido and Ruiz Cabello
1991; Garrido et al., 1993; Ruiz Cabello et al., 1991). Further studies have found that
most tumors start out as HLA class I positive, and as the disease progresses, the
expression of these molecules on some tumor cells is significantly reduced (Garrido et
al., 2017). This can be due to four main ways of downregulation, which include total
HLA class I loss, HLA haplotype loss, HLA class I locus (A, B, or C) selective loss, or
HLA class I allelic loss. These occur as a result of “hard” or “soft” genetic alterations,
referring to their ability to be reversed. “Hard” alterations include point mutations or
large deletions of DNA segments that can affect either β2m or the HLA heavy chains,
while “soft” alterations include transcriptional downregulation of these proteins or other
proteins within the APC. These “soft” lesions can be reversed using appropriate
cytokines while “hard” lesions are irreversible through these mechanisms. Haplotype
loss, if it occurs, is usually a “hard” alteration, as chromosome 6 loss is the most
common mechanism for this, while locus-selective loss is typically a “soft” alteration that
can be restored if cells are treated with IFN-γ or other cytokines associated with T helper
1 (TH1) or an adaptive immune response. Compound phenotypes of these alterations
are also frequently observed in cancer cells, as well as an overall unresponsiveness to
IFN that prevents the cell’s capacity to upregulate HLA class I molecules. The overall
frequency of alterations to this molecule in cancer is highly variable and can range from
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15-93% and can be heavily cell type dependent. Overall, studies indicate that tumors
start out with positive HLA class I expression and as they progress, HLA class I
expression in some cases become heterogeneous, finally ending up with negative HLA
class I expression, likely as a function of immune selection. Granuloma-like formation
around the tumor (immune cells surrounding the tumor but not infiltrating) occurs after
HLA class I expression is lost. In addition to immune selection, it has also been shown
that some cellular oncogene products can also cause a decrease in HLA class I
expression as a means of escape. Furthermore, a strong, direct correlation has been
found between high tumor HLA class I expression and regression of the metastasis.
Those lesions that progressed were harboring defects in HLA class I that were
irreversible (Aptsiauri et al., 2018; Garrido et al., 2017).
On the other hand, there have also been some studies that indicate the
expression of HLA class I molecules may lead to worse cancer prognosis. In models of
uveal melanoma, breast cancer, gastric cancer, esophageal cancer, medulloblastoma,
and lung cancer, high expression of the HLA class I molecule led to worse prognosis in
these patients while low expression was correlated with a better prognosis. Additionally,
these patients experienced increased tumor stage and grade as well as more recurrence
and metastasis (Madjd et al., 2005; Ramnath et al., 2006; Ueda et al., 2008). These
studies hint at an additional role for the HLA class I molecule in cancers and other
diseases.

1.5 HLA class I molecules and their role beyond the immune system

There has been increasing evidence that HLA class I molecules may also be
playing a role beyond their immune function. This is illustrated by studies that indicate
interactions with growth receptors may occur or that dimers of these molecules exist
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under certain conditions. Additionally, it has been found in models of transplantation
biology that HLA class I molecules can affect cell proliferation, migration, and apoptosis,
likely through interaction with surface receptors as HLA class I molecules, even though
they have phosphorylation sites on their cytoplasmic tails, are not able to induce
intracellular signaling alone (Gur et al., 1990; Tsai and Reed 2014). The interactions
that have been found to occur between the HLA class I molecule and various growth
factor/surface receptors in cell types such as Chinese hamster ovary (CHO) cells,
murine liver cells, and B lymphoblasts include interactions with insulin and insulin like
growth factor receptor (IR and IGF-1R respectively), epidermal growth factor receptor
(EGFR), fibroblast growth factor receptor (FGFR), and integrins, specifically integrin beta
4 (ITGB4) (Schreiber et al., 1984; Trajkovic-Arsic et al., 2013; Tsai and Reed 2014;
Zhang et al., 2010). Furthermore, cross-linking of HLA class I molecules can activate
intracellular signaling cascades and certain allotypes of HLA class I molecules (e.g.,
HLA-B27) can form dimers with one another that contribute to disease such as
ankylosing spondylitis (Campbell et al., 2012).
One of the first receptor systems that was studied in relation to interaction with
the HLA class I molecule was the IR/IGF-1R system (Trajkovic-Arsic et al., 2013).
Previous studies have indicated that the interactions between these receptors and HLA
class I molecules have been found to occur in a variety of cell lines and that these
interactions subsequently alter the downstream signaling pathways that become
activated upon stimulation of these receptors (Cousin et al., 1987; Hsu and Olefsky
1993; Kittur et al., 1987; Samson et al., 1986). These downstream signaling pathways
are affected through the ability of the HLA class I molecule to increase ligand sensitivity
of these receptors as well as to alter receptor internalization, as found in B lymphoblasts,
human and murine liver cells, and Chinese hamster ovary (CHO) cells (Cousin et al.,
1987; Hsu and Olefsky 1993; Kittur et al., 1987; Samson et al., 1986). The
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autophosphorylation of IGF and insulin receptors is also affected by HLA class I
molecules, providing another mode of action for these molecules to affect downstream
signaling pathways (Hansen et al., 1989; Ramalingam et al., 1997; Reiland and Edidin
1993; Stagsted et al., 1990; Stagsted et al., 1993). Additional research has also
indicated that this interaction is likely to occur through the HLA class I α1 domain
(through the use of a murine α1 peptide). Furthermore, it has been demonstrated that
β2m is able to associate with these receptors, indicating that β2m could be necessary for
these interactions and downstream signaling effects to occur (Centrella et al., 1989; Hsu
and Olfesky 1993; Olson et al., 1994; Stagsted et al., 1990).
EGFR is another receptor that has been reported to interact with HLA class I
molecules. This interaction was observed in A431 epidermoid carcinoma cells as well
as in normal human fibroblast cells. Treatment of these cells with antibody (either
monoclonal or polyclonal) against HLA class I molecules (pan-HLA class I antibody)
reduced the surface display of EGFR, while binding of EGF to EGFR in turn inhibited the
binding of the HLA class I antibody. Furthermore, it was noted that anti-HLA class I
antibodies reduced the ability of EGF to bind to both A431 epidermoid cells and human
foreskin fibroblasts (HFF) by reducing the number of receptors available for it to bind.
This was shown to be an immediate effect. Interestingly, fixed cells did not display this
phenomenon, and therefore this study postulated that a metabolic requirement could be
at play. Further experiments indicated that divalent antibodies were needed, suggesting
that cross-linking of the HLA class I molecule was necessary for this process to occur.
However, use of inhibitors against patching/capping did not block these effects of HLA
class I antibodies on EGF binding. Therefore, this led to the idea that HLA
internalization was not leading to EGFR internalization, but likely that there is a
conformational change in EGFR that affects the ability to bind to ligand (Schreiber et al.,
1984).
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Interestingly, it has also been found that EGFR has the ability to regulate the
expression of HLA class I molecules on the cell surface, consistent with some
oncogenes being able to control HLA class I expression in cancer cells. Cetuximabmediated inhibition of EGFR in a model of head and neck cancer (HNC) led to an
upregulation of HLA expression (which is more prominently seen with HLA-B/C than
HLA-A), implying that the functionality of EGFR leads to down-regulation of HLA class I
expression (Srivastava et al., 2015). A further study showed this same phenotype and
found that these alterations in HLA class I expression may be due to effects of EGFR
signaling on the expression of CIITA mRNA, which has direct effects on the promoters of
both HLA class I and class II genes. It was found that the mRNA levels of CIITA were
modulated by this EGFR inhibitor treatment, leading to this speculation. Further studies
have confirmed this phenotype in multiple cancer types, including mesothelioma, lung
cancer, gastric cancer, and esophageal cancer (Pollack et al., 2011).
An additional receptor with which HLA class I molecules have been found to
interact is FGFR. This interaction was found to occur in transplantation biology models
using endothelial cells and smooth muscle cells. Studies have found that when cells
were treated with HLA class I antibodies, ligation of HLA class I molecules occurred.
Additionally, upon ligation, there was an induction in the expression of FGFR, as well as
increased binding of its ligand bFGF (Bian et al., 1998; Harris et al., 1997). This
induction of FGFR expression and ligand binding in turn led to an increase in
downstream signaling, ultimately leading to an increase in cell proliferation (Jin et al.,
2005). It was further shown that treatment with a pan-HLA class I antibody was able to
stimulate cell proliferation at a greater rate as compared to antibodies against either
HLA-A or HLA-B alone (Bian et al., 1997; Bian et al., 1998; Harris et al., 1997). This
indicates that the intensity of signal transduction is related to the total number of class I
molecules on the cell surface and is likely not isotype specific. Further studies from this
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same group investigated the downstream signaling that occurs upon treatment with HLA
class I antibodies and the effect that this has on FGFR signaling. It was found that soon
after treating endothelial cells with a pan-HLA class I antibody (within one minute posttreatment), there was an increase in the tyrosine phosphorylation of the proteins Src and
Fyn, which also led to the phosphorylation of the protein p70 (Jin et al., 2002). This is
important because it was shown previously that recruitment of these molecules usually
happens upon growth factor or integrin stimulation (Jin et al., 2002). Additionally, in this
same study, the molecules FAK and paxillin were found affected by Src inhibition,
specifically the inhibition of Src prevented the subsequent tyrosine phosphorylation of
these molecules. Downstream of FAK and paxillin, the actin cytoskeleton was indicated
as being crucial in the signaling process (Jin et al., 2002). Later studies determined that
the actin cytoskeletal proteins Rho and Rho-kinase were activated and increased stress
fiber formation occurs upon HLA class I molecule ligation, indicating their involvement
downstream of HLA class I molecule ligation by antibodies (Jin et al., 2005).
Furthermore, pan-HLA class I antibody concentration and level of HLA class I surface
expression also dictates the transduction of certain downstream signals. High levels of
pan-HLA class I antibody trigger FGFR expression and lead to increased cell
proliferation, while lower concentrations alternatively stimulate PI3K/AKt signaling and
lead to the upregulation of anti-apoptotic proteins (Jindra et al., 2006). Overall, the data
indicate that HLA class I clustering, mediated by the antibodies against these molecules,
leads to activation of FGFR, which promotes stress fiber formation and cell proliferation
through a mechanism of enhanced tyrosine phosphorylation of Src, FAK, and paxillin.
In addition to interactions with FGFR, transplantation biology models have also
shown that interactions between HLA class I molecules and ITGB4 occur (Figure 1.7).
These studies indicated that this interaction was likely occurring via the cytoplasmic tail
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Figure 1.7. Schematic of one of the signaling pathways in which HLA class I molecules
are involved. In transplantation biology models, it has been shown that HLA class I
molecules interact with ITGB4 and lead to downstream signaling changes that can
influence cell proliferation and survival.

Figure from:
Zhang X, Reed EF. HLA class I: an unexpected role in integrin β4 signaling in
endothelial cells. Hum Immunol. 2012;73(12):1239-1244.
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Figure 1.7.
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of the HLA class I molecule and that deletion of the cytoplasmic domain of this molecule
impaired downstream signaling. When ITGB4 was knocked down in this endothelial cell
model of transplantation, there was an abrogation of the ability of HLA class I to
stimulate the phosphorylation of Akt, ERK, and Src as well as to affect cell proliferation
(Zhang et al., 2010). The opposite trend was seen when the amount of HLA class I was
reduced by siRNA transfection, whereby the ability of ITGB4 to stimulate the
phosphorylation of ERK and the migration of cells on laminin-5 was reduced.
Additionally, when using siRNA to knock down total HLA class I molecules, β2m, or
ITGB4, there was a decrease in the migration of these endothelial cells (Figure 1.8).
These studies also indicate that these effects involved cis interactions between HLA
class I and ITGB4 (Zhang et al., 2010). ITGB4-mediated migration was found to be
dependent upon its interactions with HLA class I as well. It is possible then that the
targeting of treatment to block the interactions between ITGB4 and HLA class I might
lead to better therapeutic strategies in transplant rejection. It has been hypothesized that
this may also apply to cancers, since ITGB4 has been implicated in the progression of
many cancer types (Zhang and Reed 2012). The different isotypes of the HLA class I
molecule are differentially expressed on various tissue types, with certain combinations
of isotypes being more prevalent on some cell types compared to others. Whether or
not HLA class I isotypes or various allotypes differ in their binding to growth factors or
downstream signaling capabilities has not yet been fully elucidated, although some
preliminary data have indicated that this may in fact be the case (Jin et al., 2011).
In addition to binding to other growth factor receptors, certain allotypes of the
HLA class I molecules have been found to form homodimers. One disease found to be
linked to certain allotypes of HLA class I molecules is ankylosing spondylitis, which is
linked to HLA-B27 (Brewerton et al., 1973; Schlosstein et al., 1973). This particular
allotype has been found to have the capacity to form
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Figure 1.8. HLA class I molecules and β2m affect migration of endothelial cells.
Endothelial cells were transfected with control siRNA or with siRNA against ITGB4, HLA
class I heavy chain, or β2m, and wound closure was assessed and quantified.
Figure from:
Zhang X, Rozengurt E, Reed EF. HLA class I molecules partner with integrin β4 to
stimulate endothelial cell proliferation and migration. Sci Signal. 2010;3(49):ra85.
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disulfide bonds between cysteine 67 in the peptide binding groove of two HLA-B27
heavy chains. Dimers formed between these molecules are present both on the cell
surface as well as in the ER (Campbell et al., 2012). However, the role these dimers
play in this particular disease has yet to be fully elucidated.
Based on the ability of HLA class I molecules to interact with cell-surface/growth
factor receptors, studies in endothelial and smooth muscle cells investigating
downstream signaling and functional changes related to these interactions have also
been done. One study showed that exposure of endothelial cells in transplantation
biology models to low concentrations of HLA class I ligating antibodies promoted cell
survival via the activation of the PI3K/Akt signaling pathway, which in turn regulates the
expression of anti-apoptotic proteins (Jin et al., 2004). Phosphorylation of Src and FAK
is upstream of PI3K and Akt phosphorylation following ligation of HLA class molecules
(Jin et al., 2007). Overall, the model that was proposed was that HLA class I molecules
transduce signals that lead to the formation of a complex featuring Src, FAK, and PI3K
that causes the phosphorylation of Akt and thereby increases the expression of antiapoptotic proteins Bcl-2 and Bcl-xL and decreases the pro-death factor Bad by its
sequestration into a complex with 14-3-3 protein (Jin et al., 2004). Moreover,
knockdown of FAK led to an inhibition of Src, PI3K (p85 subunit), and Akt
phosphorylation upon HLA class I-specific antibody treatment (Jin et al., 2007).

There

was also abrogation of paxillin phosphorylation seen upon HLA class I antibody
treatment and a blockade of the formation of actin stress fibers. The knockdown of FAK,
however, did not cause the modulation of expression of FGFR that is usually seen with
HLA class I ligation, but it did block the stimulation of cell proliferation that is usually
seen. Thus, FAK has been implicated as being a key regulator of HLA class I-induced
cell survival and proliferation and as a key upstream tyrosine kinase controlling anti-HLA
class I antibody signaling. Changes in the functions of FAK could be due to the plethora
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of phosphorylation sites that it has or due to the diverse intracellular locations to which it
and its binding partners localize (Jin et al., 2007). Additional studies by this group
indicate that HLA class I molecules and/or integrin ligation can also lead to
phosphorylation of ERK through mTORC2 (Jindra et al., 2008). Also, it was previously
shown that cross-linking of the HLA class I molecule with class I specific antibodies
activates Rho signaling, triggering reorganization of the cytoskeleton and formation of Factin stress fibers. Proteomic studies using tandem mass spectrometry further revealed
that CDK2 (an already known regulator of HLA class I signaling) was among the 35
kinase families that could be responsible for activation of downstream pathways. TPM4,
p70S6k, and eIF4A1 were other proteins that were also found to be relevant (Zhang et
al., 2012).
Overall, these studies reveal a multitude of non-immune functions for HLA class I
molecules that appear to be very complex. Further investigation into the roles these
molecules have outside of the immune system, especially in regards to cancer, is
needed to better understand the pathobiology of this disease.

1.6 HLA class I molecules and amyloid precursor-like protein 2 (APLP2)

1.6.1 APLP2 in the nervous system
Amyloid precursor-like protein 2 (APLP2) is one of three members of the amyloid
precursor protein (APP) family of proteins, along with APP and APLP1 (Jacobsen and
Iverfeldt 2009; Shariati and De Strooper 2013; Walsh et al., 2007). These proteins are
considered type 1 membrane glycoproteins (Slunt et al., 1994; Walsh et al., 2007). APP
and APLP2 are broadly expressed while APLP1 is only present in tissues of the nervous
system (Kim et al., 1995; Slunt et al., 1994). There is growing knowledge about both
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APP and APLP2, with APP being the most studied of the protein family members due to
its ability to yield the pathogenic amyloid beta plaque that contributes to Alzheimer’s
disease. This pathogenic fragment generated from APP is not formed by the other
family members (Goedert 1987; Hardy and Selkoe 2002; Mawuenyeta et al., 2010;
Pandey et al., 2016).
APLP2 has been most frequently studied for the various functions it plays within
the nervous system and only recently has it been found to be linked with cancer. APLP2
KO mice exhibit generally subtle phenotypes but do have some retinal abnormalities
likely due to abnormal morphology of the outer plexiform layer of the retina (Dinet et al.,
2016; Heber et al., 2000; Muller et al., 2017; von Koch et al., 1997; Weyer et al., 2011).
Additionally, APLP2 KO mice display hyperinsulinemia (Needham et al., 2008). There
does seem to be some compensation between members of the family, however, since
double KO of APLP2 with either APP or with APLP1, or triple KO of all three proteins,
causes death within one day of birth (Klevanski et al., 2014; Klevanski et al., 2015; von
Koch et al., 1997). Mice lacking both APLP1 and APP are viable and fertile (Heber et
al., 2000). The APP and APLP2 double KO mice have severe neuromuscular junction
deficits among various other issues, including elevated copper levels in the liver and
cerebral cortex likely contributing to their early death (Caldwell et al., 2013; Klevanski et
al., 2014; Klevanski et al., 2015; Wang et al., 2005; Yang et al., 2007). Interestingly,
keratinocytes from these double KO mice also display decreased cell proliferation and
migration (Siemes et al., 2006).
APLP2 is a multimodal protein involved in many processes. Some of the
functions within the nervous system in which APLP2 participates are cell proliferation,
cell adhesion, neurite outgrowth, mitosis segregation, cell signaling, metabolism and
transcriptional regulation (Cappai et al., 1999; Guo et al., 1998; Li et al., 1999;
Rassoulzadagan et al., 1998; Thinakaran et al., 1995). Additionally, APLP2 and APP
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can function as both cell surface receptor-like proteins or even as ligands (through their
secreted N-terminal forms) (Muller et al., 2017). Further studies have shown that the
expression of APLP2 is regulated by subcellular localization, complex cleavage events,
and post-translational modifications (Muller et al., 2017).

1.6.2 Influence of APLP2 on HLA class I molecules
Our lab has previously published many studies on the association between
APLP2 and both human and mouse MHC class I molecules and how, in some cancers,
this can affect MHC class I cell-surface expression. These previous studies have
indicated that, in S2-013 pancreatic cancer cells, APLP2 and HLA class I molecules colocalize extensively in cytoplasmic vesicles while control receptors do not (Tuli et al.,
2009b). These cytoplasmic vesicles mainly included early endosomes and, to a lesser
extent, recycling endosomes. In HeLa cells, there was also association between these
two proteins in early endosomes, but they were also co-localized in the Golgi complex
(Tuli et al., 2008a; Tuli et al., 2009a; Tuli et al., 2009b). Additionally, APLP2 can bind to
MHC class I molecules at the cell surface as well as to MHC class I molecules that have
been endocytosed. Higher expression of APLP2 resulted in an increase in the
endocytosis of HLA class I molecules (Tuli et al., 2009a). Previous studies indicated that
APLP2 is endocytosed by a clathrin-mediated route, and that APLP2 re-channels MHC
class I molecules into the clathrin-mediated endocytosis pathway, which could account
for the diversity in the literature about the route of MHC class I internalization (Huet et
al., 1980; Radhakrishna and Donaldson 1997). Additionally, HeLa cells that
experimentally overexpress APLP2 have longer retention of MHC class I molecules
within the cell, suggesting that APLP2 reduces the recycling of MHC class I molecules to
the cell surface (Tuli et al., 2008a). Furthermore, inhibition of lysosome function leads to
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an accumulation of MHC class I molecules in the lysosome, indicating that APLP2associated endocytosis of the MHC class I molecules leads to their removal from the cell
surface and subsequent degradation by the lysosome (Tuli et al., 2008a). The endocytic
capacity of APLP2, as well as its ability to promote MHC class I endocytosis, is mediated
by the NPTYKYL sequence, specifically by the middle tyrosine residue (Tuli et al.,
2009b). Interestingly, mutation of this residue does not affect the ability of APLP2 to
bind to MHC class I molecules. The interaction between these molecules has been
mapped to the conserved α3/transmembrane/cytoplasmic region as well as the
polymorphic α1/α2 membrane-distal region of the MHC class I molecule (Tuli et al.,
2008b) (Figure 1.9).
Studies from our lab also showed that APLP2 binds more strongly to certain
allotypes than others in S2-013 cells. These cells express both HLA-A2 and HLA-A24;
APLP2 binds both HLA-A allotypes but even more strongly to HLA-A2 than to HLA-A24
(Tuli et al., 2009b). In regards to mouse MHC heavy chain specificity, studies indicate
that APLP2 binds more strongly to Kd than other murine MHC class I molecules and that
β2m is needed for this binding (Morris et al., 2003; Sester et al., 2000; Tuli et al., 2008b).
Specifically, in relation to cancer, APLP2 has been found to influence the
expression of the HLA class I molecule on the surface of various cancer cell lines.
When APLP2 was overexpressed in the cancer cell line MDA-MB-435S, there was a
reduction in the surface expression of HLA-A24 as well as a reduction in the total cellsurface MHC class I expression. This was further confirmed in HeLa cells that were
transfected with HLA-A24 and overexpressed APLP2 (Morris et al., 2003; Tuli et al.,
2008a; Tuli et al., 2008b). Studies done in a pancreatic cancer cell model as well as a
Ewings sarcoma model show the overexpression of APLP2 in cancer cells (Peters et al.,
2012; Peters et al., 2013b). Furthermore, in Ewings sarcoma cell lines, APLP2 and HLA
class I were shown to interact and, when these cells were treated with ionizing radiation,
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Figure 1.9. APLP2 affects the endocytosis of both murine and human MHC class I
molecules. APLP2 and HLA class I interact near the plasma membrane. APLP2
influences the endocytosis of the HLA class I molecule through a clathrin-dependent
mechanism. Furthermore, HLA class I recycling is reduced by APLP2 by routing it to
lysosomes for degradation.

Figure from:
Peters HL, Tuli A, Sharma M, Naslavsky N, Caplan S, MacDonald RG, Solheim JC.
Regulation of major histocompatibility complex class I molecule expression on cancer
cells by amloid precursor-like protein 2. Immunol Res. 2011;51:39-44.
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Figure 1.9.
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it caused an increase in the amount of APLP2 at the cell surface (Peters et al., 2013a;
Peters et al., 2013b). This increase in APLP2 led to a decrease in the amount of HLA
class I molecules present on the cell surface. This decrease in HLA class I molecules
on the cell surface was found to be abrogated with knockdown of APLP2 using siRNA
(Peters et al., 2012; Peters et al., 2013b). The high expression of APLP2 typically seen
in cancer cells may explain the decrease in HLA class I molecules that is characteristic
of cancer cells.

1.7 Dissertation hypothesis

The immunologic functions of HLA class I molecules and their allotypes has been
well studied, however, not much work has been done looking into the role that this
molecule and its components play outside of the immune system, especially in cancer.
Therefore, the overall aim of this dissertation was to investigate the role that the
components of the HLA class I molecule (the HLA heavy chains and β2m) play in
pancreatic cancer cell migration. This was done in pancreatic cancer since pancreatic
cancer cells retain relatively high expression of HLA class I molecules and the prognosis
for this disease, especially for the large population with metastatic disease, is the lowest
for any major solid tumor. Increased knowledge of the pathobiology of this lethal
disease is, therefore, urgently needed.
Firstly, due to the interest in β2m in cancer but the lack of studies done in
pancreatic cancer specifically, the role that β2m plays in affecting the migration of
pancreatic cancer cells was investigated. Based on other studies indicating that this
molecule may have a role in affecting the migration of cancer cells, it was hypothesized
that β2m promotes pancreatic cancer cell migration. Studies done to address this
hypothesis were to knock down β2m in a variety of pancreatic cancer cell lines and a
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non-transformed pancreas cell line and evaluate changes in migration. Previous studies
from our lab have indicated that APLP2 is a protein that binds to HLA class I molecules
in pancreatic cancer, that β2m is necessary for this interaction, and that decreases in
expression of this protein contribute to pancreatic cancer metastasis. Therefore,
interactions with APLP2 as well as changes in APLP2 expression were also investigated
as a potential mechanism for any migratory changes that were observed upon
knockdown of β2m.
Additionally, as has been shown in transplantation biology models, HLA class I
heavy chains possess the ability to promote migration of smooth muscle cells and
endothelial cells. Studies have further indicated that this function may also extend to a
medulloblastoma model. Therefore, it was further hypothesized that HLA class I
molecules will not only be amply expressed in pancreatic cancer cells but that their
presence will lead to alterations in pancreatic cancer cell migration. Due to sequence
differences between isotypes as well as allotypes and the fact that expression of certain
allotypes has been linked to worse disease in cancer patients, it was further
hypothesized that the effects of the HLA class I molecule on migration will not only be
heavy chain isotype dependent, but will also be dependent on specific heavy chain
allotypes. To test this hypothesis, transient transfections using isotype-specific siRNA to
knock down HLA class I isotypes as well as transfections of designed siRNA to knock
down specific allotypes were performed, and migration was assessed in multiple
pancreatic cancer cell lines. Furthermore, as it has been previously shown, the HLA
class I molecule itself cannot cause downstream signaling, and it is necessary for it to
interact with other receptors on the cell surface to promote downstream processes, such
as cellular migration. The receptors that were investigated were integrins which have
been previously studied in relation to cancer cell migration, and EGFR, another protein
known to affect pancreatic cancer cell migration. Both of these proteins have been
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previously mentioned to either interact with or be affected by HLA class I molecules.
Thus, integrins and EGFR were hypothesized to interact with HLA class I molecules and
dictate any changes observed in cell migration upon knockdown of the different forms of
the HLA class I molecule.
Finally, the effects of the HDAC inhibitor M344 on APLP2 processing as well as
the expression of HLA class I molecules in pancreatic cancer cells was determined.
M344 has previously been shown to affect the expression of the BACE1 proteolytic
enzyme, which cleaves APLP2 and leads to formation of C-terminal fragments. As
these C-terminal fragments have been shown to affect pancreatic cancer cell
proliferation and migration as well as to interact with HLA class I molecules in this model,
it was hypothesized that treatment of the S2-013 pancreatic cancer cell line with M344
will lead to a reduction in APLP2 C-terminal fragments which will, in turn, cause a
decrease in proliferation and migration in these cells. Additionally, as previously shown
by our laboratory, reduction in APLP2 as well as its C-terminal fragment leads to an
increase in the expression of HLA class I molecules, therefore, it is expected that HLA
class I molecules will increase in S2-013 cells upon M344 treatment. This could
potentially have important implications for immunotherapy treatment in this disease.
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CHAPTER 2: Materials and Methods
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2.1 Cell Lines and Culture Conditions

2.1.1 Human Pancreatic Cancer Cell Lines
S2-013 and BxPC-3 pancreatic cancer cells (Iwamura and Hollingsworth 1999)
were grown in RPMI base medium supplemented with 10 mM HEPES, 2 mM Lglutamine, 1 x MEM NEAA, 1 mM sodium pyruvate, 100 units/ml penicillin and 100
μg/mL streptomycin, and 10% heat inactivated FBS. S2-013 cells are a wellcharacterized subclone of the SUIT2 pancreatic cancer cell line (Taniguchi et al., 1992).
Both cell lines were generously donated by Dr. Tony Hollingsworth (UNMC). PANC-1
and MIA PaCa-2 cell lines (Iwamura and Hollingsworth 1999) were grown in DMEM
base medium supplemented with 10 mM HEPES, 2 mM L-glutamine, 1 x MEM NEAA, 1
mM sodium pyruvate, 100 units/mL penicillin and 100 μg/mL streptomycin, and 10%
heat inactivated FBS. PANC-1 cells were generously donated by Dr. Michel Ouellette
(UNMC) and MIA PaCa-2 cells were purchased directly from ATCC. All cell lines were
tested for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit.
Additionally, all cells were authenticated by short tandem repeat deoxyribonucleic acid
profiling analysis (UNMC Molecular Diagnostics Facility) or purchased directly from
ATCC.

2.1.2 Human Pancreatic Ductal Cell Lines
hTERT-HPNE cells were cultured as previously described (Lee et al., 2003).
Briefly, this includes 75% glucose-free DMEM, 25% Medium M3, 5% heat inactivated
fetal bovine serum, 5.5 mM glucose, 10 ng/ml epidermal growth factor, and 50 μg/mL
Geneticin. These cells were generously donated by Dr. Michel Ouellette who also
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generated this cell line at UNMC. Cells were tested for mycoplasma contamination
using the MycoAlert Mycoplasma Detection Kit.

2.1.3 Treatment of Pancreatic Cancer Cells with Growth Factors
Pancreatic cancer cell lines were treated with either epidermal growth factor
(EGF) or transforming growth factor β (TGF- β). The day after transfection, medium on
transfected cells was replaced with either fresh maintenance medium alone or fresh
maintenance medium with either 20 ng/ml EGF or 10 ng/ml TGF-β. 48 hours posttreatment, cells were either collected for signaling experiments or were replated per the
migration assay protocol listed below to assess changes in migration.

2.1.4 Treatment of Pancreatic Cells with the HDAC Inhibitor M344
Pancreatic cancer cell lines were treated with the HDAC inhibitor M344 at the
indicated concentrations and timepoints. Briefly, 24 hours after cell plating, cells were
treated with inhibitor for the indicated timepoints and assessed for cell proliferation,
migration and viability.

2.2 Genetic manipulation

2.2.1 Short-interfering (si)RNA constructs
The β2m-specific siRNA used for β2m downregulation was the ON-TARGETplus
SMARTpool siRNA which contains four separate β2m-specific siRNA purchased from
Thermo Scientific Dharmacon (L-004366-00-0020). Pan siRNA specific to either HLA-A
and HLA-B heavy chain isotypes were also ON-TARGETplus SMARTpool siRNA
purchased from Themo Scientific Dharmacon (L-012850-01-0020 and L-013203-00-
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0020 respectively). siRNA targeting specific allotypes of the HLA class I molecule were
designed with the help of Nuzhat Khan and were ordered customly. The following
sequences were used for each: siRNA sequence against HLA-A2:
GCAUAUGACUCACCACGCUUU, siRNA sequence against HLA-A24:
CCAAGACACAUAUGACCCAUU, siRNA sequence against HLA-B7:
GGGCAUGACCAGUACGCCUUU, siRNA sequence against HLA-B59:
AGACCAACACACAGACUUAUU. ON-TARGETplus non-targeting siRNA pool (Thermo
Scientific Dharmacon D-001810-10-50) was used as a negative control.

2.2.2 Transient Transfection of siRNA
Transfections were performed following the siRNA manufacturer’s instructions for
cells in base maintenance medium. Briefly, cells were plated 24 hours prior to
transfection at a concentration of 1x105 cells/well (or 1.5x105 cells/well for hTERT-HPNE
cells due to slower growth) in a 6 well plate. On the day of transfections, cells were
starved in base maintenance medium for approximately three hours. DharmaFECT
Transfection Reagent. No. 1 (Thermo Scientific Dharmacon T-2001-03) was incubated
with 0.4 pmol of siRNA for β2m or 0.2 pmol of siRNA for all forms of the HLA heavy chain
siRNA for 30 minutes at room temperature and the mixture was added drop-wise to the
well. Four hours post-transfection, serum-containing medium was added to each well.
Confirmation of knockdown of respective proteins was evaluated at indicated times posttransfection by immunoblot analysis of cell lysates or by flow cytometry for HLA class I
allotypes.

2.3 Antibodies
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2.3.1 Anti-HLA class I component antibodies
Total HLA class I molecules for flow cytometry were detected by the W6/32
antibody which recognizes all isotypes of HLA class I molecules when bound to β2m.
This antibody was provided courtesy of Dr. Ted Hansen (Shields and Ribaudo 1998).
To recognize the HLA-A isotype for western blot, the HLA-A specific rabbit monoclonal
antibody was used (Abcam). For flow cytometry, HLA-A2 was recognized by BB7.2 was
produced from a hybridoma obtained from ATCC (Parham and Brodsky 1981). HLAA24 was detected by flow cytometry using an HLA-A24 (and HLA-A23) specific antibody
purchased from OneLambda. To recognize HLA-B heavy chain isotypes for western
blot, an HLA-B specific rabbit monoclonal antibody (Novus) or the HC-10 antibody that
recognized HLA-B and HLA-C isotypes and some HLA-A allotypes were used. The HC10 antibody was also kindly provided by Dr. Ted Hansen (Carreno and Hansen 1994;
Stam et al., 1990). The BB7.1 antibody (Thermo Scientific) was used to detect HLA-B7
by flow cytometry. The antibody 30-5-7 (which recognized the mouse H-2Ld molecule
and not HLA class I molecules) was also kindly provided by Dr. Ted Hansen
(Washington University School of Medicine, St. Louis, MO, USA) (Ozato et al., 1980;
Sernee et al., 1998; Solheim et al., 1993; Solheim et al., 1995). The 64-3-7 monoclonal
antibody (recognizes Ld that has an open, peptide-free groove and not HLA class I
molecules) was also kindly provided by Dr. Ted Hansen (Washington University School
of Medicine, St. Louis, MO, USA) (Cox et al., 1991; Smith et al., 1993; Smith et al.,
1995) To detect β2m, a β2m-specific antibody from Cell Signaling was used.

2.3.2 Additional antibodies
APLP2 full length protein antibodies that detect both the full length protein as well
as GAG-APLP2 was purchased from R&D Systems. An antibody specific to the Cterminal cleaved fragment of APLP2 was made for the Solheim lab by Thermo Scientific.
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EGFR and ITGB1 antibodies were purchased from Bethyl Laboratories and Santa Cruz
Biotechnology. Antibodies against pFAK Y397, FAK, and BACE1 were purchased from
Cell Signaling Technologies. Loading control antibodies against Hsc70 was purchased
from Enzo LifeSciences as well as pan-actin purchased from Cell Signaling
Technologies.

2.4 Cell Lysis

2.4.1 Cell lysate collection for Western blotting
Cells were harvested and washed once with cold phosphate-buffered saline
(PBS) and then resuspended in cell lysis buffer. Cell lysis buffer is composed of 1 mM
EGTA, 1 mM EDTA, 50 mM Tris-HCL pH 7.5, 1% Triton X-100, 1 mM Na3VO4, 2 mM
DTT, 0.1 mM PMSF, and 1 μg/ml Halt Cocktail. Cell lysates were stored at -80°C
overnight, then thawed on ice and centrifuged at 13,000 rpm for 30 min at 4°C.
Supernatants were transferred to new tubes and stored at -80°C.

2.4.2 Cell pellet collection for immunoprecipitation
Cells at approximately 1x107 cells were trypsinized and collected in 15 ml conical
tubes. Cell pellets were then washed with a solution of 20 mM IAA in PBS three times
spinning at 1500 rpm at 4°C for 5 mins. After the final wash, supernatant was
completely removed and cell pellets were stored at -80°C until use.

2.5 Immunoprecipitation
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Cell pellets were lysed in 1% CHAPS lysis buffer (1% CHAPS in PBS (pH 7.4),
200 mM IAA, and 0.2 mM PMSF) and incubated along with primary antibody for 3 hours
while rotating at 4°C. Following this incubation, cells were spun at 4°C for 30 minutes at
13,000 rpm. Cells were then incubated with either Protein A Sepharose beads alone
(mouse primary antibody) or a mixture of 75% Protein A and 25% Protein G beads
(rabbit primary antibody) for 1 hour gently mixing every 10 minutes. Cells were then
washed 4 times with ice-cold wash buffer (0.1% CHAPS, 200 mM iodoacetamide in Trisbuffered saline pH 7.4). The first two washes and centrifugations (at 1,100 rpm for 5
minutes at 4°C) were done immediately after cell resuspension, and the last 2 washes
included a 10 minute incubation on ice followed by centrifugation at 1,100 rpm for 5
minutes at 4°C. Elution buffer (125 mM Tris pH 6.4, 2% w/v SDS, 12% v/v glycerol, and
0.02% bromophenol blue) was then added to the Protein A-Sepharose bead mixture and
boiled for 5 minutes followed by a final spin at 1100 rpm for 5 minutes at 4°C. The
supernatant was then collected followed by a quick spin to pellet any leftover beads.
Samples were then stored at -80 C until electrophoresis.

2.6 Electrophoresis and Western Blotting

Aliquots of lysate supernatants were mixed with 5 x sodium dodecyl sulfate
loading dye (250 mM Tris-HCL pH 6.8, 10% w/v sodium dodecyl sulfate, 30% v/v
glycerol, 5% v/v β-mercaptoethanol, 0.02% bromophenol blue) and boiled for 5 minutes
prior to loading. Samples were then brought up to a volume of 15 ul with 1x SDS
loading buffer. Samples were then loaded on Invitrogen Novex Tris-glycine
polyacrylamide pre-cast 4-20% or 10-20% gels (Thermo Fisher Scientific).
Electrophoresis was performed at 90 V at room temperature and proteins were then
transferred to PVDF membranes at room temperature at 40 volts for either 1.5-2.5 hours
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depending on weight of the proteins of interest. The Kaleidescope protein marker was
used to determine the running length of the proteins of interest. Following the transfer,
the membranes were blocked in 5% w/v solution of nonfat dry milk in PBST for one hour
at room temperature while gently rocking. Membranes were then incubated with
indicated primary antibodies overnight while rocking at 4°C. After primary antibody
incubation, membranes were washed 3 times for 5 minutes at room temperature with 1%
Tween-20 in PBS solution. Subsequently, membranes were incubated with the
appropriate HRP-conjugated secondary antibodies for one hour at room temperature
with gentle rocking and were again washed with 1% Tween-20 in PBS. For protein
visualization, membranes were incubated in Pierce ECL Western Blotting Substrate and
exposed to Carestream BioMax MR film. The intensity of the protein bands were
quantified by densitometry using the LiCOR Image Studio Lite software.

2.7 Simple Western

Cell lysates were prepared as seen above and β2m protein levels were evaluated
by a Protein Simple Peggy Sue instrument per the manufacturer’s instructions. Briefly,
lysates were mixed with Simple Western sample dilution buffer (Protein Simple) that
contains a reducing agent and fluorescent standards, heated at 95°C for 5 minutes and
were loaded at a final protein concentration of 0.04 mg/ml. Lysates, primary antibody
against β2m and actin (Cell Signaling Technologies 12851 and 4968 respectively, both
used at a concentration of 1:50), horseradish peroxidase-conjugated anti-rabbit
secondary antibodies (Protein Simple, used at the manufacturer’s dilution), separation
and stacking matrix along with the chemiluminescent substrate were distributed into the
appropriate wells in a 384 well plate which was then placed into the Peggy Sue
instrument allowing for automatic running of 8 cycles. Run settings were adjusted to a
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35 minute run time from the default of 40 minutes with the 12-230 size separation
module used. Compass software (Protein Simple) was used for analysis of the
generated data.

2.8 Flow Cytometry

Cells were collected at 1x106 cells/ml and 100 ul were added to each well at a
concentration of 1x105. Cells were then spun down at 1500 rpm for 5 minutes at 4°C
and were resuspended in FACS buffer (0.2% BSA and 0.1% sodium azide). Cells were
incubated with primary antibody for 30 minutes at 4°C. Following primary antibody
incubation, cells were washed three times with FACS buffer and spun at 1500 rpm for 5
minutes at 4°C between each wash. Cells were incubated with a PE-conjugated
secondary antibody or with a PE-conjugated isotype control for 30 minutes at 4°C. Cells
were again washed three times followed by centrifugations at 1500 rpm for 5 minutes at
4°C. Samples were then transferred to tubes and analyzed on a BD FACSCalibur or
LSRII instrument with the assistance of the UNMC Cell Analysis Facility.

2.9 Analysis of Cell Migration

2.9.1 Transwell assay
Post-transfection, cells were analyzed for changes in migration by using a
transwell assay. Briefly, 72 hours post-transfection, cells were plated at 1x105 cells in
base maintenance media into a 8-m insert and were incubated for 24 hours at 37C.
After 24 hours, inserts were stained using the Hema 3 Stat Pack (Thermo Fisher) and
mounted onto slides. Three random fields of each insert were taken and all cells in each
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field were counted. For analysis of cells treated with M344, cells were treated with M344
for 24 h and then replated in inserts in serum free base maintanence media without
drug. The same protocol was then followed for M344 drug treated migration assays.

2.9.2 Scratch assay
Cells were seeded at 1.5x105 cells in a 6 well plate and were treated with 10 μM
of M344 for 24 hours. Plates were then scratched with a 200 μl pipette time and media
was replaced with drug-free maintenance media contained 10% serum. Pictures of
approximately the same location were taken at time of scratch as well as 8, 12, and 26
hours post-scratch.

2.10 Analysis of Cell Viability

Cell viability was assessed at the various indicated timepoints post-transfection
by use of trypan blue staining. Briefly, cells were collected and resuspended with trypan
blue stain and counted using a hemacytometer. Both live and dead cells were counted
and analysis was performed with percentage being total number of live cells by the total
number of cells (both live and dead).

2.11 Analysis of Cell Growth and Proliferation

2.11.1 MTT assay
Cell growth and proliferation were assessed by MTT assay. Briefly, 48 hours
post-transfection cells were replated at 2500 cells/100 μl in a 96 well plate. Lysates
were collected at this timepoint to confirm knockdown of the protein of interest and a 0
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hour timepoint MTT was performed at this time to confirm accurate cell plating between
conditions. At the indicated timepoints post-replating MTT assays were performed to
assess cell proliferation. For the actual assay, 50 ul of MTT reagent was added to 100
ul of media and incubated at 37 C for two hours. Post-incubation, all media was
removed and 100 ul of DMSO was added and plates were read at 570 nm.
For antibody-treatment MTTs and M344-treatment MTTs, cells were plated at
2500 cells/100 μl and incubated for 24 h. Cells were then treated with antibody or drug
for the indicated timepoints and the same protocol was then followed for plate reading.

2.11.2 Trypan Blue exclusion assay
To measure cell proliferation by trypan blue staining, the same protocol was
followed as for measuring cell viability except only live cells were counted at the
indicated timpoints.

2.12 Statistical Analysis

All statistical analysis was performed using the two-tailed Students t-test with the
criterion set for significance at p ≤ 0.05. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Error bars
are representative of standard error of the mean (SEM).
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CHAPTER 3: Function of β2m in pancreatic cancer cell migration

Data in this chapter have been published in the following manuscript:
Sliker BH, Goetz BT, Peters HL, Poelaert BJ, Borgstahl GEO, Solheim JC. Beta 2microglobulin regulates amyloid precursor-like protein 2 expression and the migration of
pancreatic cancer cells. Cancer Biol Ther. 2019;epub ahead of print.
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3.1 Introduction to β2m and APLP2

β2m is a 12-kD light chain that non-covalently binds and stabilizes the MHC class
I heavy chain, thereby enabling its presentation of an antigenic tumor-derived or
pathogen-derived peptide to a cytotoxic T cell. The presentation of the antigenic peptide
leads to lysis of the targeted malignant or infected cell bearing the MHC molecule
(Collins et al., 1995; Krangel et al., 1979; Townsend A et al., 1989). Surprisingly, β2m’s
expression has been noted to be maintained (and in some cases even elevated), instead
of being down-regulated, within a variety of different solid tumors, including renal cell
carcinoma, oral squamous cell carcinoma, breast cancer, prostate cancer, colorectal
cancer, and esophageal cancer (Bossard et al., 2012; Chen et al., 2008; Huang et al.,
2006; Li et al., 2014; Nomura et al., 2006; Tanaka et al., 2012). β2m is also elevated in
the serum of patients with lymphoid malignancies, including lymphomas, leukemias, and
multiple myeloma (Cooper and Plesner 1980; Josson et al., 2011; Molica et al., 1999).
For esophageal, colorectal, and oral cancers, as well as hematological malignancies,
several publications have shown that higher β2m expression within the tumor is
correlated with worse disease and poorer prognosis (Bataille et al., 1983; Bossard et al.,
2012; Chen et al., 2008; Cooper and Plesner 1980; Molica et al., 1999; Tanaka et al.,
2012). For renal cell carcinoma and oral squamous cell carcinoma, β2m increases tumor
cell migration and possibly epithelial-to-mesenchymal transition (Bataille et al., 1983;
Chen et al., 2008; Nomura et al., 2006). Thus, for these abovementioned cancers, the
data suggest that besides its immunological, anti-cancer function in antigen
presentation, β2m could also potentially have a pro-tumor function. However, despite
the reputation of pancreatic cancer as a highly metastatic disease, whether or not the
migration of pancreatic cancer cells is increased by β2m has not thus far been reported.
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APLP2, a member of the amyloid precursor protein family of proteins, is
expressed in a transmembrane form and as cleaved forms, with secretion of the large
outer domain and retention within the cell of the small C-terminal portions (Walsh et al.,
2007). Some splice forms of APLP2 are post-translationally modified on the extracellular
domain by a chondroitin sulfate glycosaminoglycan (GAG) (Walsh et al., 2007). APLP2
expression has been noted to be high in pancreatic cancer, as well as in some other
cancers (Abba et al., 2004; Moss et al., 2007; Peters et al., 2012; Peters et al., 2013).
Previous studies from our laboratory have indicated that APLP2 associates with mouse
and human MHC class I molecules and reduces MHC class I cell-surface expression
(Peters et al., 2011; Sester et al., 2000; Tuli et al., 2009a; Tuli et al., 2009b).
Furthermore, we demonstrated that APLP2 increases pancreatic cancer cell migration in
vitro and causes more metastasis to distant organ sites in a mouse orthotopic pancreatic
cancer xenograft model (Pandey et al., 2015). Whether APLP2’s pro-migratory effect on
pancreatic cancer cells is linked to the interactions of APLP2 with any component of
MHC class I molecules, including β2m, is a question that has not previously been
addressed.
Thus, the focus of this study was to investigate whether β2m influences the
migration of pancreatic cancer cells, and, if so, to assess potential involvement of APLP2
in the mechanism. The human pancreatic cancer cell lines that we analyzed were found
to express substantial levels of β2m. When pancreatic cancer cell expression of β2m was
experimentally down regulated by siRNA transfection, the migration of S2-013 and
PANC-1 pancreatic cancer cells was significantly decreased, but in contrast the
migration of MIA PaCa-2 was significantly increased. The β2m/HLA class I/peptide
complexes in the S2-013 and PANC-1 pancreatic cancer cell lines, but not the MIA
PaCa-2 cell line, associate with APLP2. Reduction in β2m, by siRNA transfection, in turn
down regulated the expression of APLP2 in S2-013 and PANC-1. However, knockdown
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of β2m by siRNA transfection in MIA PaCa-2 cells up regulated the expression of APLP2
in that cell line, in accordance with the effect of β2m knockdown on migration capability.
Thus, our data indicate that β2m is amply expressed in pancreatic cancer cells, and that
β2m regulates APLP2 expression, and, correspondingly, affects the migration of
pancreatic cancer cells. Therefore, our findings suggest that β2m could be a potential
factor influencing pancreatic cancer metastasis, acting via APLP2.

3.2 β2m in pancreatic cancer cell migration

3.2.1 β2m is amply expressed in pancreatic cancer cells
To assess the level of β2m expressed in pancreatic cancer cell lines, we
analyzed lysates of several pancreatic cancer cell lines (S2-013, PANC-1, and MIA
PaCa-2) along with an immortalized, non-transformed pancreas cell line (hTERT-HPNE)
for comparison. As shown in Figure 3.1, all of the cell lines express β2m at a level
comparable to the non-transformed hTERT-HPNE cell line. These data suggest that,
despite its immunological function as a component of the HLA class I molecule, β2m
expression is not necessarily lost or down regulated in human pancreatic cancer cell
lines.

3.2.2 β2m’s influence on pancreatic cancer cell migration
To investigate whether β2m increases pancreatic cancer cell migration, we
transfected S2-013, PANC-1, and MIA PaCa-2 pancreatic cancer cell lines with siRNA
specific for β2m (or with control scrambled siRNA). As a control, the non-transformed
pancreatic cell line hTERT-HPNE was also transfected with β2m-specific or scrambled
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Figure 3.1. β2m is amply expressed in human pancreatic cancer cell lines. Simple
Westerns to detect actin (as a control), as well as for β2m, were performed on cell
lysates from hTERT-HPNE (an immortalized but not transformed pancreatic cell line)
(left panel) and from pancreatic cancer cell lines (left panel: S2-013, PANC-1; right
panel: PANC-1, MIA PaCa-2). The results shown are representative of experiments
performed on 3 separate lysates of each cell type to assess the levels of β2m in these
cell lines.
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Figure 3.1.
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siRNA. After siRNA transfection, the down regulation of β2m protein in the cell lines was
verified (Figure 3.2). By transwell assay, we determined that the migration rates of S2013 and PANC-1 were significantly impaired when β2m expression was down regulated
(Figure 3.2). In contrast, when we down regulated β2m expression in MIA PaCa-2 cells
with siRNA, the migration rate increased significantly (Figure 3.2). The hTERT-HPNE
pancreatic cell line is less migratory than the pancreatic cancer cell lines, and there was
not a significant diminishment nor enhancement of migration when β2m was knocked
down in these cells (Figure 3.2). These findings indicate that β2m influences the
migration rate of pancreatic cancer cells, but not of normal pancreatic cells.

3.3 β2m and APLP2 in pancreatic cancer

3.3.1 HLA class I molecules (in complex with β2m) interact with APLP2
Earlier studies in our laboratory showed that APLP2 is highly expressed in
pancreatic cancer cells, and that APLP2 increases pancreatic cancer cell migration in
vitro and facilitates metastasis in an orthotopic mouse xenograft model (Pandey et al.,
2015; Peters et al., 2012). In addition, we had previously demonstrated that APLP2
associates with β2m/HLA class I/peptide complexes in S2-013 cells (Tuli et al., 2009a)
To investigate if a relationship exists between APLP2 and β2m in the promotion of
pancreatic cancer cell migration, we first performed co-immunoprecipitation experiments
on lysates of pancreatic cancer cell lines (S2-013, PANC-1, and MIA PaCa-2). The
antibody W6/32 is very well established as having specificity for β2m/HLA class I/peptide
complexes (Carreno and Hansen 1994; Ladasky et al., 1999; Parham et al., 1979;
Shields et al., 1998). Immunoprecipitations were done with the W6/32 antibody (and
control immunoprecipitations were also performed). The immunoprecipitates were
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Figure 3.2. β2m knockdown by siRNA decreases the migration rate of S2-013 and
PANC-1 pancreatic cancer cells, increases the migration rate of MIA PaCa-2 pancreatic
cancer cells, and does not significantly alter the migration of non-transformed hTERTHPNE pancreatic cells. Simple Westerns were performed on lysates of the indicated
cells to confirm knockdown of β2m at 72 h post-transfection. Actin was used as the
control. To assess migration, transwell assays were performed with each of the cell
lines. Cells were replated 72 h post-transfection into 8-m inserts and incubated for 24 h.
Three random fields were photographed and counted and graphed based on the
average numbers of migrated cells. For the S2-013 cell line, the results from 9 separate
migration experiments were compiled, for PANC-1, data were acquired in 8 separate
experiments, and for MIA PaCa-2 there were 5 repetitions of the migration experiment
performed. The protein expression data shown correspond to one of the migration
experiments with each cell line, and are representative of the whole set of data obtained
to confirm knockdown for each of the experiments. The statistical significance of the
results was analyzed with Student’s two-tailed t test and the P values are shown on the
graphs. Each error bar represents the standard error of the mean.
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Figure 3.2.
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immunoblotted with an antibody for APLP2, along with an antibody for the HLA class I
heavy chain, as a control to verify the success of the immunoprecipitation. As shown in
Figure 3.3, the immunoblots demonstrate the association of APLP2 with the HLA class I
heavy chain/β2m/peptide complex in S2-013 (as previously reported) (Tuli et al., 2009a)
and in PANC-1 cells, but not in MIA PaCa-2 cells. Association of higher molecular
weight GAG-APLP2 with the HLA class I molecules was not observed in any of these
cell lines (data not shown). HLA class I heavy chains are highly polymorphic, (Robinson
et al., 2015; Robinson et al., 2016) and their extensive polymorphism may account for
the association of APLP2 with HLA class I molecules in the S2-013 and PANC-1
pancreatic cancer cell lines but not the MIA PaCa-2 cell line.

3.3.2 Effects of β2m knockdown on APLP2 protein levels
To further investigate if a linkage might exist between APLP2 and β2m in
facilitating pancreatic cancer cell migration, we next evaluated the effect of β2m on the
level of APLP2 in the pancreatic cancer cell lines. We observed a diminution of both
GAG-APLP2 and APLP2 expression when β2m siRNA was transfected into the S2-013
pancreatic cancer cell line (Figure 3.4). In addition, it was also evident that β2m
knockdown reduced the level of APLP2 in the PANC-1 cell line (Figure 3.4). The
PANC-1 cell line expresses very little GAG-APLP2 (Figure 3.4). Knockdown of β2m in
MIA PaCa-2 had a distinctly different effect, causing a substantial increase, rather than a
decline in both APLP2 and GAG-APLP2 levels. When the hTERT-HPNE cells were
transfected with β2m siRNA, there was neither substantial upregulation nor
downregulation of APLP2 or GAG-APLP2 expression (Figure 3.4).

3.3.3 Effects of β2m knockdown on HLA class I heavy chains
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Figure 3.3. APLP2 associates with β2m/HLA class I heavy chain/peptide complexes in
S2-013 and PANC-1 but not MIA PaCa-2. The W6/32 antibody which only recognizes
HLA class I heavy chains when they are bound to β2m and peptide, was used for
immunoprecipitations of HLA class I molecules from lysates of S2-013, PANC-1, or MIA
PaCa-2 cells. The lanes marked (+) indicate immunoprecipitations in which cell lysates
were included, and lanes marked (-) indicate control mock immunoprecipitations in which
cell lysates were omitted. As a negative control, an isotype-matched mouse IgG
antibody (the 30-5-7 antibody) was used, which has specificity for the mouse MHC class
I molecule Ld and not for HLA class I molecules. After electrophoresis, the proteins on
the gel were transferred to a membrane and probed with anti-APLP2 antiserum to reveal
APLP2 (or the higher molecular weight GAG-APLP2) or with the HC10 antibody to verify
HLA class I immunoprecipitation.
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Figure 3.4. β2m knockdown by siRNA reduces the APLP2 expression level in S2-013
and PANC-1 pancreatic cancer cells, elevates APLP2 expression in MIA PaCa-2
pancreatic cancer cells, and does not significantly change the level of APLP2 in nontransformed hTERT-HPNE pancreatic cells. The indicated cell lines were cultured with
β2m siRNA (or scrambled sequence control siRNA) for 72 h and cell lysates were
collected and tested by Simple Western for β2m (to verify β2m knockdown by siRNA) and
immunoblotted with an antibody for APLP2 or for Hsc70 (as the control). The APLP2specific antibody recognizes both APLP2 and the high molecular weight GAG-modified
form of APLP2. The results shown are representative of 5 independent experiments for
S2-013, PANC-1, and MIA PaCa-2, and of 2 independent experiments for hTERTHPNE.
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For comparison, we also examined the impact on the HLA class I heavy chain
level when β2m expression was knocked down in pancreatic cancer cell lines. When
β2m expression was down regulated by siRNA, the HLA class I heavy chain expression
was lower for all three of the pancreatic cancer cell lines tested (PANC-1, MIA PaCa-2,
and S2-013) (Figure 3.5). Thus, HLA class I heavy chain expression is linked to β2m
expression and consistently decreases in coordination with β2m, likely due to rapid
turnover of the HLA class I heavy chains when β2m is not available to stabilize it. These
findings indicate that the increase in APLP2 (and GAG-APLP2) in MIA PaCa-2 is not due
to a global rise in protein expression when the cells are deficient in β2m, since the
expression of the control Hsc70 protein in unchanged (Figure 3.4) and the expression of
the HLA class I heavy chain is decreased (Figure 3.5).

3.4 Discussion

Even though β2m is a subunit of the HLA class I molecule that presents tumor
antigens marking pancreatic cancer cells as cytotoxic T cell targets, our findings with
pancreatic cancer cell lines (Figure 3.1) suggest that β2m is not typically down regulated
in pancreatic cancer. A study utilizing immunohistochemical staining demonstrated that
β2m is amply expressed in human pancreatic cancer tissue (Liu et al., 2015). In
addition, two data sets on β2m protein expression in pancreatic tumor cells are included
in the Human Protein Atlas (https://www.proteinatlas.org/ENSG00000166710B2M/pathology) (Uhlen et al., 2010; Uhlen et al., 2015). Of these sets, the first reports
that 10 patients had tumors expressing β2m (with β2m not detected in 2 other patients’
tumors), and the second set reports that 11 of 11 patients’ tumors expressed β2m (6 with
high, 4 with medium, and 1 with low expression). These results on human pancreatic
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Figure 3.5. β2m knockdown by siRNA causes a deficiency in HLA class I heavy chain
expression in all three pancreatic cancer cell lines tested. S2-013, PANC-1, and MIA
PaCa-2 cells were cultured with β2m siRNA (or scrambled sequence control siRNA) for
72 h and cell lysates were collected. The lysates were tested for β2m by Simple
Western (to verify β2m knockdown by siRNA) and immunoblotted for the HLA class I
heavy chain (with antibody HC10) or for a control protein (actin for S2-013 and Hsc70 for
PANC-1 and MIA PaCa-2). The results shown are representative of 8 independent
experiments for S2-013 and of 3 separate experiments for PANC-1 and MIA PaCa-2.
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Figure 3.5.

71
cancer tissue are commensurate with our findings of β2m at substantial levels in
pancreatic cancer cell lines.
We found that β2m increases the migration of two pancreatic cancer cell lines
(PANC-1 and S2-013), and decreases the migration of a third (MIA PaCa-2) (Figure
3.2). In our analysis of the mechanism by which β2m exerts these effects on pancreatic
cancer cell migration, we assessed the possible role of APLP2 in its effects, since we
had previously shown APLP2/HLA class I molecule association in S2-013 cells and we
had demonstrated by transwell and wound healing assays that APLP2 is a pro-migratory
and pro-metastasis protein in pancreatic cancer cells (Pandey et al., 2015; Tuli et al.,
2009a; Wen et al., 2003). Consistent with our theory that APLP2 might be linked to
β2m’s effect on pancreatic cancer cell migration, we observed that APLP2 coimmunoprecipitates with the β2m/HLA class I heavy chain/peptide complex specifically in
the same two pancreatic cancer cell lines for which β2m increases migration (PANC-1
and S2-013) (Figure 3.3). Upon knockdown of β2m, the expression of APLP2 was also
decreased selectively in S2-013 and PANC-1, but increased in MIA PaCa-2 (Figure
3.4). In contrast, knockdown of β2m was not selective in regard to its effect on HLA
class I expression, as it caused a decline in the level of HLA class I heavy chain in all
three cell lines (Figure 3.5).
Although APLP2 is known to regulate the migration of pancreatic cancer cells
(Pandey et al., 2015), our understanding of how it does so is incomplete. We previously
showed that APLP2 knockdown in a pancreatic cancer cell line has a dramatic impact on
the actin cytoskeleton (Pandey et al., 2015). Therefore, APLP2 regulation of actin
polymerization may be responsible for its ability to increase the rate of migration
(Pandey et al., 2015). In Drosophila, APLP2 was also recently reported to facilitate cell
migration via c-Jun N-terminal kinase phosphorylation (Wang et al., 2018). APLP2
(called YWK-II in this case), when bound by Müllerian-inhibiting substance in YWK-II-
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transfected CHO cells, triggers signaling that results in ERK1/2 activation (Huang et al.,
2000; Yin et al., 2007). In a separate study that used APLP2-transfected CHO cells,
APLP2 was found to act as an adhesion protein in response to fibronectin and type IV
collagen, which are both present in the extracellular matrix. Furthermore, in some
publications, the GAG group on APLP2 has been suggested to contribute to APLP2’s
ability to assist in migration (Guo et al., 1998; Li et al., 1999), and so the GAG moiety
may contribute, potentially by altering extracellular matrix interactions in vivo.
APLP2 and MHC class I molecules associate in a variety of cell types
(Feuerbach and Burgert 1993; Morris et al., 2003; Peters et al., 2013; Tuli et al., 2008a;
Tuli et al., 2008b; Tuli et al., 2009a; Tuli et al., 2009b). The subcellular itinerary of
associated APLP2 and MHC class I molecules has been analyzed in earlier studies.
More APLP2 is associated with MHC class I molecules when the adenovirus E3/19K
protein (which has a natural endoplasmic reticulum retention sequence) is present in
cells (Feuerbach and Burgert 1993; Morris et al., 2003; Sester et al., 2000), which
indicates that APLP2/MHC association starts in the endoplasmic reticulum. APLP2
interaction with MHC class I molecules is dependent on the presence of β2m (Sester et
al., 2000). We have also demonstrated that APLP2 is co-localized with MHC class I
molecules in the Golgi and in early endosomes and recycling endosomes (Tuli et al.,
2008a; Tuli et al., 2009a; Tuli et al., 2009b). In addition, in our previous work, we found
that APLP2 and MHC class I molecules are associated at the cell surface and internalize
together into early endosomes by a process that requires Tyrosine 755 in the APLP2 Cterminal region (Tuli et al., 2009a)
Together, these findings suggest that β2m (as part of the complete HLA class I
molecule) potentially exerts a stabilizing effect on HLA-associated APLP2 proteins in S2013 and PANC-1 at the cell surface, where APLP2 could contribute to migration via
interactions with the extracellular milieu. Alternatively, since MHC class I molecules co-
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localize with APLP2 in the recycling endosome and in the lysosome, (Tuli et al., 2009a;
Tuli et al., 2009b) β2m (as an MHC class I molecule component) that is associated with
APLP2 may delay the release of secreted APLP2 at the surface from recycled
endosomes and/or retard the degradation of APLP2 in the lysosome.
Notably, in MIA PaCa-2 cells, in which APLP2 and β2m/HLA class I/peptide
complexes do not detectably associate, the level of APLP2 is still influenced by β2m;
however, both APLP2 expression and cell migration are actually increased when β2m
expression is knocked down in these cells (Figure 3.2 and Figure 3.4). In MIA PaCa-2,
APLP2 and β2m/HLA class I/peptide complexes may be interacting but in a more
unstable or transient manner, preventing detection. The knockdown of β2m by siRNA
might cause a distinctive change in the localization of APLP2, in comparison to its
localization in S2-013 and PANC-1, with subsequent effects on the APLP2 level and cell
migration. With or without inducing an alteration in APLP2 subcellular localization, the
absence of β2m might alter APLP2 interaction with other intracellular proteins, perhaps
due to the resultant increased level of APLP2. Besides the MHC class I molecule,
APLP2 has been shown to associate with several other proteins. For example, in brain
tissue APLP2 interacts with RAC1, PP2ac, and RHOA, which are also expressed in the
pancreas and have known functions in pancreatic cancer cell migration. (Bai et al., 2008;
Ungefroren et al., 2018; Melzer et al., 2017; Mu et al., 2018; Witte et al., 2017; Wu et al.,
2014). Furthermore, a small (6-kilodalton) C-terminal fragment of APLP2 associates
with the CP2 transcription factor and stimulates the expression of glycogen synthase
kinase (GSK)-3 (Xu et al., 2007). Although this APLP2/GSK-3 study was not done
with pancreatic cancer cells, its findings could potentially have a relationship to
pancreatic cancer too, as GSK-3 is a protein that has been linked to pancreatic cancer
invasiveness (Kitano et al., 2013).
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It may be relevant to our findings that MIA PaCa-2 differs from PANC-1 and S2013 in the type of K-ras mutation and TP53 mutation. MIA PaCa-2 has Kras Gly12Cys
and mutant TP53 Arg248Trp mutations, whereas S2-013 and PANC-1 have alternative
mutations in Kras and TP53 that are more commonly found in pancreatic cancer cells
(ExPASy Bioinformatics Resource Portal https://web.expasy.org/cellosaurus). The
presence of the Gly12Cys mutation in Kras has been previously noted in other cancer
cell types to alter signaling pathways. In non-small cell lung cancer cells, Kras Gly12Cys
leads to activated Ral signaling and a decline in growth factor-dependent Akt activation,
whereas Kras Gly12Asp cells have activated PI3K and MEK signaling (Ihle et al., 2012).
Additionally, MIA PaCa-2 but not PANC-1 is sensitive to a MEK inhibitor used without
concurrent Akt inhibitor, due to the MIA PaCa-2 Kras Gly12Cys mutation (Brauswetter et
al., 2017). Thus, MIA PaCa-2 utilizes signaling pathways that are separate from those of
S2-013 and PANC-1, and that may intersect with APLP2 in different manners and with
distinct outcomes.
HLA class I molecules are encoded by three genetic loci (HLA-A, B, and C); thus,
there are three HLA class I isotypes. Furthermore, as mentioned above, HLA class I
heavy chains are extremely polymorphic, with an enormous number of allele products
(protein allotypes), (Robinson et al., 2015; Robinson et al., 2016) and such
polymorphism may influence the presence or absence of association of APLP2 with
specific β2m/peptide/HLA class I allotype complexes that are disparate among
pancreatic cancer cell lines. To determine whether MHC class I polymorphism dictates
whether or not APLP2 can associate with specific β2m/HLA class I/peptide complexes in
pancreatic cancer cells, we have begun an examination of the impact of individual HLA
class I heavy chains allotypes on APLP2 expression in pancreatic cancer cells.
Preliminary results from our experiments that are underway show very interesting
patterns of HLA class I heavy chain isotype-specific and polymorphic allotype-specific
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effects on APLP2 expression, but these are sufficiently complex as to be beyond this
scope of this report.
In total, our discoveries indicate that β2m significantly affects the migration of
pancreatic cancer cells, and so may play a role in regulating pancreatic cancer
metastasis. The Human Protein Atlas indicates a significantly lower survival probability
for pancreatic cancer patients who have higher levels of tumor β2m expression
(https://www.proteinatlas.org/ENSG00000166710B2M/pathology/tissue/pancreatic+canc
er#ihc), which is consistent with our findings of increased migration for the S2-013 and
PANC-1 cells when β2m is not knocked down. Pancreatic cancer is extremely
metastatic, and it is a high and rising cause of cancer-related mortality (Rahib et al.,
2014; Siegel et al., 2018). The five-year survival rate is already among the worst for any
major cancer, with only ~7% of patients in 2018 expected to survive past this mark
(Siegel et al., 2018). Acquisition of information about the factors likely to add to the
metastatic pathobiology of this disease, from studies such as this one, will improve our
comprehension of pancreatic cancer and potentially contribute to the development of
better therapeutic approaches to target it.
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CHAPTER 4: HLA-B and its effects on pancreatic cancer cell migration
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4.1 Introduction to HLA-B and integrins

HLA class I molecules are composed of a heavy chain, the light chain β2m, and
endogenous peptide (Krangel et al., 1979). These heavy chains are encoded by three
separate genetic loci that encode for three similar yet not completely identical
sequences, which are termed isotypes. These isotypes include an –A, -B, and –C
isotype (Townsend et al., 1989). These molecules are best known for being part of the
adaptive immune system and presenting antigens to cytotoxic T cells. Peptide
presentation to T cells leads to lysis of the target cell and this allows for protection
against viral infection or malignant transformation (Benacerraf 1981). Recently, in the
field of transplantation biology, HLA class I molecules have been implicated in affecting
processes such as cell migration (Zhang et al., 2010). In terms of cancer, although
these molecules can be down-regulated as a form of immune escape, there have been
studies in various cancer types, including medulloblastoma and breast, gastric, and lung
cancer have shown that high expression of these molecules can be associated with poor
prognosis (Madjd et al., 2005; Ramnath et al., 2006; Smith et al., 2011; Ueda et al.,
2008). Furthermore, HLA class I molecules were found to promote increased
medulloblastoma cell migration upon addition of exogenous β2m, which stabilizes cellsurface HLA class I heavy chains that have released their β2m light chains after arrival at
the plasma membrane, through an ERK1/2-mediated mechanism (Smith et al., 2009;
Smith et al., 2011). However, even though pancreatic cancer is known for its high rate
of metastasis, an investigation of the role HLA class I molecules in cell migration in this
disease has not been reported. Additionally, the function that specific isotypes have in
this process has also never been fully addressed.
A few previous studies in transplantation biology models have indicated that
integrins interact with HLA class I molecules and that this interaction can contribute to
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cell migration in these models (Zhang et al., 2010; Zhang and Reed 2012). Integrins are
cell surface molecules that function as heterodimers and that are present on nearly all
nucleated cells. There are 8 α subunits and 18 β subunits that can pair together to form
24 distinct functional heterodimers. A specific range of heterodimers can exist on
particular cell types and they function mainly to bind to certain components of the
extracellular matrix (ECM) (Bianconi et al., 2016; Ginsberg 2014; Hynes 2002). The
α2β1 heterodimer binds mainly to collagen but also has the ability to bind to laminin,
fibronectin, and E-cadherin (Giancotti and Ruoslahti 1999; Gout et al., 2001; Plow et al.,
2000; Stipp 2010; Tuckwell et al., 1995; Whittard et al., 2002). This heterodimer is
overexpressed in many cancer types including pancreatic cancer and is associated with
an aggressive disease phenotype (Danen 2005; Grzesiak et al., 2006; Grzesiak et al.,
2007; Guo and Giancotti 2004; Madamanchi et al., 2010; McCall-Culbreath and Zutter
2008; Mizejewshi 1999). The α2β1 heterodimer also was shown to promote the
migration of pancreatic cancer cells as well as various other cancer cell types such as
gastric cancer and prostate cancer (Bassaganas et al., 2014; Chuang et al., 2018;
Grzesiak et al., 2006; Grzesiak et al., 2011; Hall et al., 2008; Yang et al., 2003).
Whether an interaction exists between integrins and HLA class I molecules in pancreatic
cancer and if this interaction contributes to pancreatic cancer cell migration has yet to be
addressed.
Thus, the focus of this study was to investigate whether the specific HLA-B
isotype influences the migration of pancreatic cancer cells, and if so, to assess the
potential involvement of integrin β1 (ITGB1) and integrin α2 (ITGA2) in this mechanism.
The human pancreatic cancer cell lines that we analyzed were found to express
substantial levels of HLA-B. When expression of HLA-B was experimentally downregulated by siRNA transfection using a pan-HLA-B siRNA in pancreatic cancer cell
lines, the migration of S2-013 cells was significantly increased while in contrast the
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migration of PANC-1 and MIA PaCa-2 cells was significantly reduced. From
examination of overall protein expression of ITGB1, it was found that in S2-013 cells,
there was an increase in ITGB1 expression when HLA-B expression was knocked down.
In the PANC-1 and MIA PaCa-2 cells, there was conversely a decrease in ITGB1
expression. Similar results were observed for the S2-013 cell line when surface
expression of ITGB1 was investigated. Since ITGB1 is able to form a heterodimer with
ITGA2, ITGA2 was also investigated. Interestingly, total protein levels of ITGA2 did not
change in the S2-013 or PANC-1 cell line but surface expression followed the same
expression pattern as ITGB1, increasing in S2-013 cells upon HLA-B knockdown. MIA
PaCa-2 cells, however, do not express ITGA2. A downstream effector of integrin
signaling, focal adhesion kinase (FAK), show similar changes in total level of expression
and in its phosphorylation status, indicating alterations to this pathway that have the
ability to affect cell migration.
These data thus indicate that HLA-B is amply expressed in pancreatic cancer
cells and influences their migration, and that HLA-B regulates the expression of ITGB1
and correspondingly ITGA2, which together have been previously established to affect
the migration of pancreatic cancer cells. Therefore, our findings suggest that HLA-B
could be a factor that alters the migration of pancreatic cancer cells through its effects on
the α2β1 heterodimer.

4.2 HLA-B in pancreatic cancer cell migration

4.2.1 HLA-B is amply expressed in pancreatic cancer cell lines
To assess levels of HLA-B in a panel of pancreatic cancer cell lines by
immunoblotting, we analyzed lysates from S2-013, PANC-1, and MIA PaCa-2 pancreatic
cancer cell lines and compared them to hTERT-HPNE cells, an immortalized but not
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transformed pancreas ductal cell line. As shown in Figure 4.1, all of the cell lines tested
have expression of HLA-B and the expression is comparable to that in hTERT-HPNE
cells. These data suggest that, despite the well-known anti-cancer immunological
function of this molecule, the HLA-B isotype is not necessarily lost or down-regulated in
human pancreatic cancer cell lines.

4.2.2 HLA-B’s influence on pancreatic cancer cell migration
To investigate whether the HLA-B isotype affects pancreatic cancer cell
migration, we transfected S2-013, PANC-1, and MIA PaCa-2 pancreatic cancer cell lines
with siRNA specific for pan-HLA-B (or with control scrambled siRNA). After siRNA
transfection, the reduction of HLA-B protein levels was confirmed in the pancreatic
cancer cell lines tested (Figure 4.2). By transwell assay, the migration rate of the S2013 cell line was determined and was found to be significantly increased when HLA-B
expression was knocked down. In contrast, when we down-regulated the expression of
HLA-B in PANC-1 and MIA PaCa-2 cells, the migration rate was significantly impaired
(Figure 4.2). These findings indicate that HLA-B affects the migration rate of pancreatic
cancer cells.

4.3 Integrins and HLA-B in pancreatic cancer cells

4.3.1 Effects of HLA-B knockdown on integrin total protein expression
To examine what could potentially be mediating the differential effects that HLAB exerts on pancreatic cancer cell migration, integrin expression was interrogated as
integrins have a major role in cancer cell migration, including pancreatic cancer cell
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Figure 4.1. The HLA heavy chain isotype HLA-B remains abundantly expressed in
human pancreatic cancer cell lines. Immunoblots to detect HLA-B and Hsc70 (as an
internal control) were performed on an untransformed pancreas duct cell line (hTERTHPNE) and S2-013, PANC-1, and MIA PaCa-2 pancreatic cancer cell lines. The results
shown are representative of three experimental replicates to assess HLA-B in lysates
from these cell lines.
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Figure 4.1.
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Figure 4.2. The siRNA knockdown of HLA-B increases migration of S2-013 pancreatic
cancer cells but diminishes the migration of PANC-1 and MIA PaCa-2 pancreatic cancer
cells. Immunoblots were performed on lysates from the same cell lines used for
migration assays to verify knockdown of total HLA-B 72 h post-transfection. Hsc70 was
used as a loading control. The knockdown immunoblotting results shown are
representative of all experiments performed for each cell line. The migration of each
pancreatic cancer cell line was assessed by transwell assay. At 72 h post-transfection,
the cells were replated into 8-μm inserts and incubated for 24 h. Photographs were
taken of three random fields, the cells in each of the fields were counted, and the results
were graphed as average number of cells migrated. For each cell line, 5 repetitions
were performed. Error bars represent standard error of the mean. Student’s two-tailed
t-test was used for assessment of statistical significance, and *p<0.05, **p<0.01,
***p<0.001.
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Figure 4.2.
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migration (Bassaganas et al., 2014; Chuang et al., 2018; Grzesiak et al., 2006;
Grzesiaket al., 2011; Hall et al., 2008; Yang et al., 2003). Due to their high prevalence in
heterodimeric form in pancreatic cancer, ITGA2 and ITGB1 were chosen to be
investigated (Danen 2005; Grzesiak et al., 2006; Grzesiak et al., 2007; Guo and
Giancotti 2004; Madamanchi et al., 2010; McCall-Culbreath and Zutter 2008; Mizejewshi
1999). Firstly, the expression levels of ITGB1 and ITGA2 were analyzed in pancreatic
cancer cell lines, tested in comparison to the hTERT-HPNE cells. Expression of both
molecules was confirmed in all pancreatic cancer cell lines tested with the exception of
MIA PaCa-2 cells, which lack expression of ITGA2 (Figure 4.3). Expression of these
integrins were then assessed upon HLA-B siRNA transfection. In the S2-013 cells,
when HLA-B was knocked down, an increase in the protein expression of ITGB1 was
observed (Figure 4.4A). Interestingly, however, no significant change in ITGA2 protein
expression was observed in this cell line when HLA-B was knocked down (Figure 4.4A).
Conversely, in PANC-1 and MIA PaCa-2 cells, there was a decrease in ITGB1
expression when HLA-B was knocked down in both of these cell lines (Figure 4.4B-C).
ITGA2 also remained unchanged in the PANC-1 cells when HLA-B was knocked down
(Figure 4.4C). MIA PaCa-2 cells do not express ITGA2 and no changes were observed
in this cell line (Figure 4.3).

4.3.2 Effects of HLA-B knockdown on integrin surface expression
Most of the effects of integrin molecules take place at the cell surface; therefore,
we interrogated if the surface expression of these molecules also follows the same trend
as total protein level. By flow cytometry, surface expression of both ITGB1 and ITGA2
was investigated on the S2-013 pancreatic cancer cell line. In these cells, when HLA-B
was knocked down, an increase in ITGB1 at the cell surface was also seen (Figure
4.5A). Interestingly, there was also an increase in ITGA2 at the cell surface,
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Figure 4.3. Expression of ITGA2 in pancreatic cancer cell lines. Lysates from hTERTHPNE non-transformed cells as well as from a panel of pancreatic cancer cell lines were
collected and immunoblotted for ITGA2 and Hsc70 (loading control). The results are
representative of experiments performed on 2 separate lysates of each cell type.
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Figure 4.4. Total expression of ITGB1 is increased in HLA-B knockdown in S2-013 cells
but decreased in expression in PANC-1 and MIA PaCa-2 cells. ITGA2 total expression
is not affected by HLA-B knockdown in either S2-013 or PANC-1 cells. Cell lysates were
collected from the abovementioned pancreatic cancer cell lines 72 h post-transfection.
Lysates were immunoblotted for ITGB1, Hsc70 (loading control), and HLA-B (by HC-10
antibody) to confirm knockdown of this protein. The results shown are representative of
(A) 2 separate experiments for S2-013. (B) For MIA PaCa-2 cells, results shown are
from one experiment. (C) For PANC-1 cells, results are shown from 2 separate
experiments.
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(B)
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Figure 4.4. (C)
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which is in contrast to total expression levels where no change was observed (Figure
4.5B).

4.4 Downstream signaling of HLA class I molecules and Integrins

One of the major and most well studied signaling molecules downstream of
integrins is FAK (Bianconi et al., 2016). FAK is a cytoplasmic non-receptor tyrosine
kinase (Parsons et al., 2000). Ligand binding leads to clustering of integrins at which
point activation of FAK by autophosphorylation at Tyr397 can occur. This position on
FAK is a binding site for other kinases including Src and PI3K (Chen et al., 1996; Cobb
et al., 1994; Schaller et al., 1994). The integrin-FAK pathway has been associated with
many aspects of pancreatic cancer metastasis such as adhesion, migration, and
invasion (Furuyama et al., 2006; Itoh et al., 2004; Kanteti et al., 2016; Miyazaki et al.,
2003). Therefore, to investigate further downstream signaling controlled by the HLA
class I molecules and the α2β1 heterodimer, pFAK Tyr397 and total FAK expression
was investigated in pancreatic cancer cell lines upon knockdown of HLA-B. HLA-B
knockdown in S2-013 pancreatic cancer cells led to an increase in pFAK Y397 similarly
to the increase in ITGB1 that was also observed as a result of HLA-B knockdown
(Figure 4.6). PANC-1 cells, which had a decrease in ITGB1, also had a decrease in
pFAK Y397 (Figure 4.6). Interestingly, in all cell types, total FAK expression followed
the same pattern as pFAK Y397 for all cell lines tested (Figure 4.6). Total FAK protein
expression has been found to be upregulated in many different cancer types including
pancreatic cancer and diminished expression of this protein can contribute to decreased
cell migration through reduction in the amount of FAK available for activation (Furuyama
et al., 2006; Itoh et al., 2004; Jiang et al., 2016; Kanteti et al., 2016; Miyazaki et al.,
2003).
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Figure 4.5. ITGB1 is increased in expression upon HLA-B knockdown in S2-013 cells.
The surface expression of ITGA2 is also higher on S2-013 cells in which HLA-B
expression has been knocked down. Cells were collected from the mentioned
pancreatic cancer cell lines 72 h post-transfection and were stained for ITGB1. Flow
cytometry was performed on cells and results were analyzed by DIVA software. The
results are from one experimental replicate.
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Figure 4.6. Expression of FAK is increased in expression upon knockdown of HLA-B in
S2-013 cells but FAK is decreased in expression in PANC-1 that have undergone
knockdown of HLA-B. Cell lysates were collected from the aforementioned pancreatic
cancer cell lines 72 h post-transfection. Lysates were immunoblotted for pFAK (Y397),
total FAK, Hsc70 (loading control), and HLA-B to confirm knockdown of this protein. The
results are representative of experiments performed on 7 separate lysates for the S2013 cell line and 2 separate lysates for the PANC-1 cell line.
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4.5 Discussion

Our findings suggest that HLA-B, even though having the capability of presenting
tumor antigens to cytotoxic T cells, remains highly expressed in pancreatic cancer cell
lines. A majority of studies investigating HLA class I molecule expression in pancreatic
cancer interrogated total HLA class I expression but did not assess differences in
expression among HLA class I isotypes in normal tissue as compared to malignant
tissue (Pandha et al., 2006; Ryschich et al., 2004; Ryschich et al., 2005; Scupoli et al.,
1996). Our findings for the first time indicate that the HLA-B isotype is not robustly
down-regulated in pancreatic cancer cell lines (Figure 4.1).
Additionally, we found that HLA-B slows the migration of a pancreatic cancer cell
line (S2-013) while it increases the migration of two other pancreatic cancer cell lines
(PANC-1 and MIA PaCa-2) (Figure 4.2). In our analysis of the mechanism by which
HLA-B exerts these effects on pancreatic cancer cell migration, we assessed the
possible role of integrins, since some integrin molecules have been demonstrated to
interact with HLA class I molecules and contribute to cell migration in an endothelial cell
model of transplantation biology (Zhang et al., 2010). ITGB1 and ITGA2 were chosen as
these proteins form a heterodimer commonly seen in pancreatic cancer (Grzesiak et al.,
2006; Grzesiak et al., 2007). Consistent with our hypothesis that the α2β1 heterodimer
is linked to HLA-B’s effect on pancreatic cancer cell migration, we observed that ITGB1
total protein expression is reduced upon knockdown of HLA-B in PANC-1 and MIA
PaCa-2 cells. Additionally, ITGB1 total protein expression was induced by HLA-B
knockdown in S2-013 cells. Furthermore, following HLA-B knockdown, α2β1 surface
expression is induced in the S2-013 cells, supporting the observed changes in migration
upon HLA-B knockdown. Downstream effector molecule pFAK Y397 and total FAK
expression followed the same trends as ITGB1in each cell line as those observed with
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indicating the induction or reduction of this downstream pathway consistent with the
observed changes in cell migration.
Although ITGA2/ITGB1 heterodimers are known to regulate pancreatic cancer
cell migration, understanding of the role that these molecules together play with HLA
class I molecules, specifically HLA-B, is incomplete. Previous studies have shown that
HLA class I molecules on the cell surface can interact with ITGB4 after stimulation of
cells with HLA class I antibody (Zhang et al., 2010). Loss of either HLA class I
molecules or ITGB4 altered signaling pathways and downstream effectors such as
pFAK, pSrc, pERK, and pAKT (Zhang et al., 2010). Pancreatic cancer cells express
other integrin heterodimers in addition to ITGA2/ITGB1; therefore, certain integrin
heterodimers not explored in this study could also be contributing to the differential
effects of HLA-B on pancreatic cancer cell migration. The potential influence of other
integrins is particularly relevant in the case of the MIA PaCa-2 cell line, which does not
express ITGA2. ITGA3, another integrin alpha chain found to heterodimerize in
pancreatic cancer, might also be mediating effects on migration under the influence of
HLA-B in MIA PaCa-2 cells. Furthermore, ITGA6, which binds to both ITGB1 and
ITGB4, also could be playing a role in conjunction with HLA-B class I molecules in
pancreatic cancer cells.
Notably, in the S2-013 cell line, HLA-B expression represses cell migration as
compared to the PANC-1 and MIA PaCa-2 cell lines, in which HLA-B was found to
induce cell migration. Interestingly, S2-013 cells express two distinct allotypes of HLA-B
while PANC-1 and MIA PaCa-2 cells express only one allotype likely having lost the
other allotype during oncogenic transformation (Table 4.1). The presence of multiple
allotypes as well as the certain sequences of the particular allotypes expressed could
lead to these differential effects on integrin molecules. Previous studies indicate that the
interaction between integrins and HLA class I molecules is mediated by the cytoplasmic
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Table 4.1. HLA-B allotypes present in the S2-013, PANC-1, and MIA PaCa-2 pancreatic
cancer cell lines.
Data generated in collaboration with the Hildebrand lab at the University of Oklahoma
Health Science Center for the S2-013 cell line. The HLA-B allotype information for the
PANC-1 and MIA PaCa-2 cells was obtained from the website:
http://celllines.tron-mainz.de/
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Table 4.1.
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tail of the HLA class I molecule (Zhang et al., 2010). A few allotypes of HLA-B, such as
HLA-B27, have also previously been found to be able to form interchain disulfide bonds
that cause homodimerization via cysteine residues in their extracellular sequences and
formation of “redox-induced dimers” of certain HLA class I molecules can occur that
involve cysteine residues in the cytoplasmic domain (Campbell et al., 2011; Campbell et
al., 2012; Lenart et al., 2012). The particular allotypes expressed by these pancreatic
cancer cell lines have not been fully investigated for the ability to form these bonds, but
HLA-B7 shares the cysteine residue present in HLA-B27 that forms these bonds. Thus,
particular sequences expressed by the specific allotypes of HLA-B present in pancreatic
cancer cells could be potential mediators of the differences observed in the effects of
HLA-B on pancreatic cancer cell migration.
Moreover, crosstalk has been found to exist between growth factor receptors and
integrins in some types of cancer such as breast and pancreatic cancer. Growth factor
receptors that intersect with integrins include EGFR, FGFR, and IGF-1R. These
intersections have also been implicated in the effects that integrins have on cancer cell
migration (Bianconi et al., 2016; Carpenter et al., 2015; Freeman et al., 2003; Fujita et
al., 2013; Morello et al., 2011). These growth factor receptors, as indicated in Chapter 1,
have also been implicated as interacting with HLA class I molecules adding another
layer of complexity to what could be occurring when HLA class I molecules are knocked
down. This intersection may be another potential mechanism that could explain the
differential effects of HLA-B on the migration of various pancreatic cancer cell lines.
Together, these findings suggest that the specific HLA class I heavy chain
isotype HLA-B influences pancreatic cancer cell migration through effects on the α2β1
integrin heterodimer and downstream signaling molecule pFAK Y397 and total FAK
protein. These discoveries indicate that HLA-B may be playing a role in pancreatic
cancer metastasis as well. Due to the high metastatic rate of pancreatic cancer and its
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continually dismal 5-year survival rate, garnering information about factors that
contribute to the migration of pancreatic cancer cells from studies such as this one will
aid in the comprehension of this dreadful disease, and may potentially contribute to the
generation of better treatments for pancreatic cancer.
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CHAPTER 5: HLA-A allotypes and their influence on pancreatic cancer cell migration
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5.1 Introduction to HLA-A allotypes and EGFR

HLA class I molecules are best known for their function within the human
immune system where they present antigenic peptides to cytotoxic T cells (Benacerraf
1981). These molecules are composed of three components: the light chain β2m, heavy
chain, and endogenous antigenic peptide (Townsend et al., 1989). One unique aspect
of these molecules is the high rate of polymorphisms that exist for the heavy chains.
There are thousands of different sequence variations for each heavy chain, which are
termed allotypes (Robinson et al., 2015; Robinson et al., 2016). Recent studies in
transplantation biology models have indicated that HLA class I molecules are able to
alter cell migration (Zhang et al., 2010). Studies have also shown that the HLA class I
molecules can interact with various growth factor receptors on the surface of cells,
including EGFR on the surface of fibroblasts, and that the interaction between EGFR
and HLA class I molecules affects ligand binding to EGFR (Schreiber et al., 1984). No
publications to date, however, have reported interaction between EGFR and HLA class I
molecules in pancreatic cancer cells, nor have investigations into how certain HLA class
I allotypes affect such interactions been conducted.
Thus, the focus of this current study was to investigate the intersection of HLA-A
allotypes and EGFR in pancreatic cancer cells and to examine how their associations
contribute to cell migration. Human pancreatic cancer cell lines (S2-013, PANC-1, and
MIA PaCa-2) were analyzed for total HLA-A expression and were found to express
substantial levels of HLA-A as compared to hTERT-HPNE (an immortalized but not
transformed pancreas ductal cell line). S2-013 cells have the HLA-A allotypes HLA-A2
and HLA-A24. The PANC-1 and MIA PaCa-2 cell lines each share one HLA-A allotype
with S2-013 expressing HLA-A2 and HLA-A24 respectively. Specifically designed
siRNAs targeting each HLA-A allotype individually were transfected into S2-013, PANC-

105
1, and MIA PaCa-2 cells, and knockdown of each HLA-A allotype in the respective cell
lines was confirmed by flow cytometry. In the S2-013 cells, when HLA-A2 was knocked
down, a decrease in migration was observed, while when HLA-A24 was knocked down,
there was a highly significant induction of cell migration. Conversely, the other two cell
lines had the opposite trend, i.e., knockdown of HLA-A2 in the PANC-1 cells induced
migration while HLA-A24 knockdown in the MIA PaCa-2 cells significantly reduced cell
migration. EGFR expression was slightly induced upon loss of HLA-A2 in PANC-1 cells,
while the opposite occurred in S2-013 cells. Thus, our data indicate that HLA-A and its
allotypes are amply expressed on pancreatic cancer cells and that HLA-A2 potentially
regulates EGFR protein expression and correspondingly affects the migration of
pancreatic cancer cells. Therefore, our findings suggest that allotypes of HLA-A could
be potential factors that influence pancreatic cancer migration and metastasis, acting
partially through EGFR.

5.2 HLA-A and its allotypes in pancreatic cancer cell migration

5.2.1 The HLA-A isotype is robustly expressed in pancreatic cancer cells
The levels of the HLA-A isotype were analyzed in several pancreatic cancer cell
lines as compared to hTERT-HPNE cells, an immortalized but not transformed pancreas
ductal cell line. As shown in Figure 5.1, all pancreatic cancer cell lines tested had levels
of HLA-A comparable to the level in the non-transformed hTERT-HPNE cells. These
data suggest that, despite the immunological function that this molecule is best known
for, HLA-A expression is not necessarily lost or robustly down regulated in human
pancreatic cancer cell lines.
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5.2.2 Effects of the HLA-allotypes on pancreatic cancer cell migration
To investigate the effects that the allotypes HLA-A2 and HLA-A24 have on
pancreatic cancer cell migration, the S2-013, PANC-1, and MIA PaCa-2 pancreatic
cancer cell lines were transfected with siRNA against their respective allotypes or with
control siRNA and knockdown was confirmed by flow cytometry (Figue 5.2A). Cell
migration upon knockdown of HLA-A allotypes was tested by transwell assay. It was
observed that in the S2-013 cells, when HLA-A2 was knocked down, there was a
significant reduction in cell migration (Figure 5.2B), while HLA-A24 knockdown in this
same cell line led to a highly significant induction in cell migration (Figure 5.2C).
Conversely, the other two cell lines showed the exact opposite trends in cell migration
compared to the S2-013 cells. In the PANC-1 cells when HLA-A2 was knocked down,
there was a significant increase in cell migration (Figure 5.2B) whereas the HLA-A24
knockdown in the MIA PaCa-2 cell line correlated with a significant decrease in
migratory capability of these cells (Figure 5.2C). These findings indicate that pancreatic
cancer cell migration is affected by HLA-A in an allotype-specific manner, but that there
are also additional factors that influence the impact of HLA-A allotypes in the various
pancreatic cancer cell lines.

5.3 HLA-A allotypes and EGFR in pancreatic cancer

5.3.1 EGFR interacts with HLA-A2 in PANC-1 cells but not with HLA-A2 in S2-013 cells
Earlier studies published by others have shown that HLA class I molecules and
EGFR associate and that this association can affect ligand binding to EGFR (Schreiber
et al., 1984). In our study, firstly, the levels of EGFR were assessed in a panel of
pancreatic cancer cell lines compared to the non-transformed hTERT-HPNE cells, and
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Figure 5.1. HLA-A is robustly expressed in pancreatic cancer cell lines. Cell lysates
from hTERT-HPNE cells as well as the S2-013, PANC-1, and MIA PaCa-2 cell lines
were collected and immunoblotted for HLA-A using a pan-HLA-A antibody. Hsc70 was
used as a loading control. The results shown are representative of experiments
performed on 3 separate lysates of each cell type.
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Figure 5.1.
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Figure 5.2. Knockdown of HLA-A allotypes affects pancreatic cancer cell migration. (A)
Pancreatic cancer cell lines were transfected with HLA-A2 or HLA-A24 siRNA, and at
72 h post-transfection the cells were probed with HLA-A2 or HLA-A24 specific antibodies
and flow cytometry was performed to confirm knockdown of allotypes in each cell lines.
The solid black peak represents isotype control, the black line represents cells
transfected with scramble siRNA and the dotted line represents cells transfected with
HLA-A allotype-specific siRNA. Data are representative of 2 separate experiments. (B)
S2-013 and PANC-1 cells were transfected with HLA-A2 siRNA and 72 h posttransfection, cells were plated in 8-μm inserts and incubated for 24 h. Inserts were then
fixed, stained, and photographed. Pictures of 3 random fields were taken and used to
determine the average number of cells that had migrated. Results for the S2-013 cell
line are a compilation of 7 separate migration experiments and data for the PANC-1 cells
are representative of 4 separate experiments. The error bars indicate the standard error
of the mean, and the standard for statistical significance was set at p<0.05; *p<0.05,
**p<0.01, ***p<0.001. (C) S2-013 and MIA PaCa-2 cells were transfected with HLA-A24
siRNA, and at 72 h post-transfection the cells were plated in 8-μm inserts and incubated
for 24 h. Inserts were then fixed, stained, and photographed. Pictures of 3 random
fields were taken and used to determine the average number of cells that migrated.
Results for the S2-013 cell line are a compilation of 5 separate migration experiments
and data for the MIA PaCa-2 cells are representative of 3 separate experiments. The
error bars indicate the standard error of the mean, and the standard for statistical
significance was set at p<0.05; *p<0.05, **p<0.01, ***p<0.001.
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Figure 5.2. (A)
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Figure 5.2. (B)
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Figure 5.2. (C)
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high levels of EGFR were observed in all cell lines tested (Figure 5.3). MIA PaCa-2
cells had slightly less expression of EGFR as compared to the other cell lines tested
(Figure 5.3). To investigate if a relationship exists between HLA-A allotypes and EGFR
in pancreatic cancer cell lines, co-immunoprecipitation experiments were first performed
on lysates of the S2-013 and PANC-1 pancreatic cancer cell lines. The BB7.2 antibody
is a well established antibody specific for the HLA-A2 heavy chain.
Immunoprecipitations of HLA-A2 with BB7.2 were performed on lysates of S2-013 and
PANC-1 cells (as both cell lines express this specific HLA-A allotype), and the
immunoprecipitates were immunoblotted with an antibody specific for EGFR. An
antibody specific to the pan-HLA-A isotype was used as a control to verify the success of
the immunoprecipitation. An association between EGFR and HLA-A2 in PANC-1 cells
was observed but this same interaction was not present in the S2-013 cells (Figure 5.4).

5.3.2 Effects on EGFR protein levels when HLA-A2 is knocked down
In addition, the impact of HLA-A2 knockdown on EGFR expression levels in
pancreatic cancer cell lines was examined. When HLA-A2 was knocked down in the S2013 cells, there was an observable decrease in EGFR total protein expression (Figure
5.5). Densitometry indicates that there is up to a 40% reduction in EGFR expression in
the S2-013 cells in which HLA-A2 was knocked down as compared to the S2-013 cells
transfected with scramble control siRNA (Figure 5.5). Conversely, when HLA-A2 was
knocked down in the PANC-1 cell line there was a slight increase in total EGFR
expression (Figure 5.5). When taking the loading control into account, densitometry
indicated that there was about a 15% induction of EGFR in PANC-1 cells (Figure 5.5).
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Figure 5.3. EGFR is highly expressed in most pancreatic cancer cell lines. Cell lysates
from hTERT-HPNE cells as well as the S2-013, PANC-1, and MIA PaCa-2 cell lines
were collected and immunoblotted for EGFR using an EGFR-specific antibody. Hsc70
was used as a loading control. The results shown are representative of experiments
performed on 2 separate lysates of each cell type.
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Figure 5.3.
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Figure 5.4. EGFR associates with HLA-A2 in PANC-1 cells but not in S2-013 cells.
BB7.2 antibody, which is specific to HLA-A2, was used for immunoprecipitations. 64-3-7
(which recognizes the mouse MHC class I molecule H2-Ld but not HLA class I
molecules) was used as a non-specific isotype control antibody. (+) indicates that cell
lysates were present while (-) indicates no cell lysates were present and antibody alone
was used as a control. Immunoblots were then performed for EGFR after the
immunoprecipitations. A pan-HLA-A antibody was used to confirm success of the
immunoprecipitation. The results shown from one experiment.
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Figure 5.5. EGFR expression is decreased in S2-013 HLA-A2 knockdown while it is
slightly increased in PANC-1 cells that have HLA-A2 knocked down. The indicated cell
lines were cultured with HLA-A2 specific siRNA (or scramble control siRNA) for 72 h and
cell lysates were collected and immunoblotted for EGFR or Hsc70 (loading control).
Densitometry was performed using Image Studio Lite software by Li-COR Biosciences.
The results shown are representative of experiments performed on 2 separate lysates
for S2-013 and are shown from one set of experiments for PANC-1 cells.
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Figure 5.5.

120
5.4 Discussion

Even though HLA-A and its allotypes are best known for presenting endogenous
antigenic peptides to cytotoxic T cells, our findings in pancreatic cancer cell lines
indicate that the HLA-A allotypes HLA-A2 and HLA-A24 are still amply expressed by
pancreatic cancer cell lines. The results from this study build upon the supposition that
particular HLA-A allotypes might be important in disease prognosis (Nagata et al., 2009;
Orgad et al., 1998), and suggest the possibility that HLA-A allotypes may affect
pancreatic cancer prognosis through regulation of the ability of cells to migrate and
metastasize.
We found that HLA-A allotypes differentially affect the migration of pancreatic
cancer cell lines in a cell type-dependent manner. HLA-A2 in S2-013 cells induces cell
migration while HLA-A2 in PANC-1 cells reduces cell migration. For HLA-A24, this
particular allotype slows the migration of S2-013 cell line while it increases the migration
of the MIA PaCa-2 cell line. Since there are many molecular subytpes of HLA-A2 and of
A24, performing detailed molecular typing of the HLA-A2 and A24 heavy chains
expressed by each of these cell lines would reveal whether they are identical at the
molecular level or only closely related, and would perhaps provide new clues as to the
mechanism whereby these HLA-A allotypes cause divergent effects on the migration of
different cell lines.
In our analysis of the mechanism by which these HLA-A allotypes exert these
effects on pancreatic cancer cell migration, we assessed the possible role of EGFR in
these differential effects. EGFR was hypothesized to exert the effects of the HLA-A
allotypes on pancreatic cancer cell migration since other studies have previously shown
that EGFR and HLA class I molecules interact with one another in epidermoid carcinoma
cells (Schreiber et al., 1984). Additionally, EGFR is highly expressed in our panel of
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pancreatic cancer cells (Figure 5.3), and it has been shown to be involved in pancreatic
cancer cell migration (Stock et al., 2014). Consistent with our hypothesis that EGFR
might be linked to the differential effects of the HLA-A allotypes on pancreatic cancer cell
migration, HLA-A2 and EGFR are associated in PANC-1 cells, while in the S2-013 cells
no association was observed between these two molecules. Additionally, EGFR protein
expression was found to be reduced in S2-013 with HLA-A2 knockdown and increased
slightly by HLA-A2 knockdown in PANC-1 cells. Studies investigating whether a similar
mechanism mediates the changes observed when the expression of the allotype HLAA24 is knocked down in pancreatic cancer cells is currently underway.
Furthermore, previous studies have shown that there is a relationship between
EGFR and APLP2. Two studies have been published thus far that demonstrated an
inverse correlation between the expression levels of these two proteins, indicating that
loss of APLP2 is associated with an increase in EGFR (Aydin et al., 2011; Zhang et al.,
2007). Specifically, in a model of Alzheimer’s disease, the mRNA of EGFR was found
to be increased in APLP2-/- mice (Aydin et al., 2011). Furthermore, in fibroblasts that had
double knockout of both APP and APLP2, there was an increase in EGFR expression
(Zhang et al., 2007). The APP intracellular domain (AICD) was found to regulate EGFR
expression, as indicated by overexpression of the AICD leading to a decrease in EGFR
(Zhang et al. 2007). AICD has been shown to regulate the transcription of multiple
genes, and the AICD and the intracellular domain of APLP2 share considerable
sequence homology indicating that there could be overlap of the functions of these
fragments (Baek et al., 2002; Kim et al., 2003; Pardossi-Piquard et al., 2005; von Rotz et
al., 2004). The AICD, in the fibroblast cell model, is thought to bind to promoter regions
of EGFR to promote its expression. This is hypothesized to occur via Fe65, which binds
and stabilizes AICD (Cao and Sudhof 2001; Kimberly et al., 2001) and that is thought to
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potentially allow translocation of AICD to the nucleus where AICD can bind to the
promoter of EGFR.
As we have previously shown, APLP2 and its C-terminal fragment are highly
expressed in pancreatic cancer cells and are increased in expression upon oncogenic
transformation (Peters et al. 2012). In S2-013 pancreatic cancer cells, interaction
between both the full-length form of APLP2 and the APLP2-CTF with HLA class I
molecules has been detected (Sliker et al., 2019; Tuli et al., 2009b). Earlier studies from
our laboratory found that these interactions could be allotype-specific, as HLA-A2 was
found to more strongly interact with APLP2 than HLA-A24 (Tuli et al., 2009b).
Additionally, previous studies by our laboratory have found that APLP2 promotes
pancreatic cancer cell migration, and that β2m, the light chain of the HLA class I
molecule, may mediate its effect on pancreatic cancer cell migration through this
molecule (Pandey et al., 2015; Sliker et al., 2019). EGFR has further been established
as a regulator of pancreatic cancer cell migration (Stock et al., 2014). No studies have
been published, however, that indicate how APLP2-CT, EGFR, and HLA-A allotypes
may interact with one another. Preliminary studies into a potential relationship between
HLA-A allotypes, APLP2-CT, and EGFR have indicated that knockdown of HLA-A2 can
induce changes in APLP2-CT, with HLA-A2 knockdown in PANC-1 pancreatic cancer
cells leading to a substantial reduction in the level of APLP2-CT (Figure 5.6).
Further reasons for the differences in the effects of disparate HLA-A allotypes on
pancreatic cancer cell migration could be minor sequence variations between these
allotypes. At this point, the necessary sequences required for the association of HLA-A
with EGFR remain unknown. Additionally, as previously mentioned, the APP
intracellular domain also plays a similar role in affecting EGFR expression (Zhang et al.,
2007). APP is highly expressed in addition to APLP2 in all of the pancreatic cancer cell
lines tested (Peters et al., 2012); therefore, it is possible that part of the differential role
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Figure 5.6. APLP2-CT expression is decreased in HLA-A2 knockdown in PANC-1 cells.
PANC-1 pancreatic cancer cells were cultured with HLA-A2 specific siRNA (or scramble
control siRNA) for 72 h and cell lysates were collected and immunoblotted for APLP2-CT
or Hsc70 (loading control). Densitometry was performed using Image Studio Lite
software by Li-COR Biosciences. The results shown are from 1 experimental replicate
for PANC-1 cells.
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Figure 5.6.
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that is seen in these cell lines could be due to an unknown input by APP. Furthermore,
HLA class I molecules can interact with other growth factor receptors such as IGF-1R
(Hsu and Olefsky 1993). APLP2 has also been found to be regulated by IGF-1
(Jacobsen et al., 2010), and therefore preferential interactions with other growth factors
receptors such as IGF-1R could also contribute to the differences among allotypes in the
same cell line as well as between cell lines.
Together, the findings from this study suggest that HLA-A allotypes, especially
HLA-A2, potentially affect pancreatic cancer cell migration through EGFR expression
regulation. These discoveries, in total, indicate that HLA-A allotypes significantly affect
the migration of pancreatic cancer cells and so may play a role in regulating pancreatic
cancer metastasis. Pancreatic cancer has the lowest 5-year overall survival rate for any
major solid tumor and is currently the 3rd leading causing of cancer related deaths in the
United States (Rahib et al., 2014; Siegel et al., 2018). Acquisition of information from
studies such as this one about the factors that could potentially be affecting the
metastatic pathobiology of this disease will improve the overall understanding of
pancreatic cancer and could potentially contribute to the development of better
treatments for this disease.
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CHAPTER 6: The HDAC inhibitor M344 and its effect on APLP2 processing
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6.1 Introduction to APLP2 processing

APLP2, along with the other members of this protein family (APP and APLP1),
undergoes cleavage by proteolytic enzymes called secretases (Walsh et al., 2007).
Sites of cleavage by the alpha-secretase ADAM10, beta-secretase BACE1, and gammasecretase have been identified within APLP2 (Hogl et al., 2011; Jacobsen and Iverfeldt
2009; Walsh et al., 2007; Zheng and Koo 2006). This cleavage results in the release of
a large extracellular domain as well as smaller C-terminal fragments (Eggert et al., 2004;
Vassar et al., 2009). Specifically, cleavage of APLP2 with either alpha or betasecretases allows the generation of an approximately 70 kD soluble ectodomain. This
cleavage is usually N-terminal to the transmembrane domain. Post-cleavage with either
alpha or beta-secretase, this leaves a transmembrane fragment approximately 10-15 kD
in size (Walsh et al., 2007). Additional cleavage of this C-terminal fragments can occur
by a gamma-secretase that creates an intracellular domain (ICD) fragment that has the
capacity to translocate to the nucleus and regulate gene transcription of actin
cytoskeletal elements and proteins such as GSK-3β (Kitano et al., 2013). Previous
studies conducted by our laboratory have shown that the 10-15 kD APLP2 C-terminal
fragment (APLP2-CT) is highly expressed in pancreatic cancer cells and that the
expression of this cleavage fragment is increased upon oncogenic transformation
(Peters et al., 2012). These studies also indicated that blockade of beta-secretase
activity using chemical inhibitors caused a reduction in the APLP2-CT level as well as a
loss of viability of pancreatic cancer cells. Conversely, the same beta-secretase inhibitor
treatment of a non-transformed pancreas cell line did not result in any observable
changes in growth or survival (Peters et al., 2012).
Of further relevance is the ability of several isoforms of APLP2 to undergo
glycosylation. Only those isoforms that exclude exon 14 are modified at Ser614 by a

128
unique O-linked glycan that can be extended by chondroitin sulfate glycosaminoglycans
(Thinkaran and Sisodia 1994; Thinkaran et al., 1995). Our studies have indicated that
this glycosaminoglycan (GAG)-modified form is highly expressed in pancreatic cancer
cells (Peters et al., 2012). Additionally, earlier studies by other groups using corneal
epithelial cells and Chinese hamster ovary (CHO) cells indicated that expression of
GAG-modified APLP2 was correlated with an increase in cell migration (Li et al., 1999).
Another study implicated this modified form of APLP2 in epithelial wound healing (Guo et
al., 1998).

6.2 Introduction to the histone deacetylase (HDAC) inhibitor M344

HDACs function to repress transcription by removing acetyl moieties from lysine
residues located on histones. HDAC inhibitors work to suppress this function and are
being used as new anti-cancer treatments (Donadelli et a., 2003; Sambucetti et al.,
1999; Xu et al, 2007). Studies using these inhibitors in cancer have indicated that they
lead to inhibition of cancer cell growth through either induction of apoptosis or reduction
in progression through the cell cycle (Huang et al., 2000; Konstantinopoulos et al., 2007;
Sowa et al., 1997). One new HDAC inhibitor is M344 (4-dimethylamino-N-(6hydroxycarbamoylhexyl)-benzamide. This drug has been found to be an anti-cancer
agent in a variety of different cancers including endometrial and ovarian carcinomas as
well as medulloblastoma and neuroblastoma. Furthermore, M344 has the ability to
increase the therapeutic response to radiation therapy in a squamous carcinoma cell
model (Furchert et al., 2007; Jung et al., 1999; Takai et al., 2006; Zhang et al., 2004).
Further studies have also indicated that M344 has an anti-proliferative impact on breast
cancer cells through the induction of apoptosis (Yeung et al., 2012). Of particular
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interest to this study is the ability of M344 to decrease the gene expression of the betasecretase BACE1 in a model of Alzheimer’s disease (Volmar et al., 2017).
Thus, the aim of this study was to investigate the effects of M344 treatment on
pancreatic cancer cell proliferation and migration through its effects on APLP2
processing. We found that M344 treatment of the S2-013 pancreatic cancer cell line led
to a significant decrease in proliferation that corresponded with increasing
concentrations of M344. This decrease in proliferation occurred at 24, 48, and 72 hours
post-treatment. Interestingly, however, there were no overall changes in cell viability
with treatment. Additionally, M344 treatment led to a highly significant decrease in the
ability of S2-103 cells to migrate. When the protein expression levels of APLP2, GAGAPLP2, and APLP2-CT were investigated post-M344 treatment, it was found that APLP2
expression did not change but there was a significant reduction in APLP2-CT upon
increasing concentrations of M344. Unexpectedly, GAG-APLP2 was found to undergo a
reduction in molecular weight from a size of 250 kD to a size of about 150 kD,
suggesting that there was a modification in the structure of the GAG moiety. Therefore,
our findings suggest that M344 affects pancreatic cancer cell proliferation and migration,
and that these effects may be mediated through the reduction of APLP2-CT expression
and changes in the GAG modification of APLP2.

6.3 M344 treatment affects processing of the APLP2 protein

6.3.1 Treatment of pancreatic cancer cells with M344 decreases the production of the Cterminal fragment of APLP2
Previous studies using M344 in an in vitro model of Alzheimer’s disease
indicated that treatment of cells with this drug led to a reduction in the protein expression
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of BACE1 (Volmar et al., 2017). BACE1 has been found to be amply present in
pancreas tissue and has been found to cleave APLP2 (Figueroa et al., 2001; Hogl et al.,
2011; Stutzer et al., 2013). Past studies in our lab have indicated that treatment of
pancreatic cancer cells with a BACE1 inhibitor led to inhibition of cell proliferation and
viability, concurrent with blockade of APLP2 cleavage (Peters et al., 2012). Therefore,
we first investigated if M344 was also affecting APLP2-CT expression in pancreatic
cancer cells. When S2-013 cells were treated with 10 μM of the M344 drug for 24, 48,
and 72 hours, there was a significant reduction in APLP2-CT at all time points examined
(Figure 6.1A). When this reduction was quantified, there was up to a 90% reduction in
APLP2-CT at 72 h post-treatment (Figure 6.1B). No observable change occurs in the
full length form of APLP2, however, indicating that the decrease observed in APLP2-CT
does not simply reflect a reduction in expression of total APLP2 but is more likely related
to alterations in its cleavage (Figure 6.1A).

6.3.2 M344 treatment reduces the molecular weight of the GAG-modified form of APLP2
APLP2 and GAG-APLP2 can be simultaneously detected by immunoblotting with
the same antibody, and by immunoblotting the GAG-APLP2 present in S2-013
pancreatic cancer cells is found to be approximately 250 kD in molecular weight.
Interestingly, when S2-013 cells were treated with 10 μM of M344, there was a
substantial reduction in the molecular weight of GAG-APLP2 (Figure 6.1A). In S2-013
cells, upon M344 treatment the molecular weight of the GAG-APLP2 band shifts down to
approximately 150 kD. GAG-APLP2 has been implicated in cell migration (Guo et al.,
1998; Li et al., 1999), and therefore this shift in GAG-APLP2 size could be a potential
mediator of any observed changes in S2-013 pancreatic cancer cell migration.
However, by what mechanism this downward shift occurs has yet to be elucidated.
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Figure 6.1. APLP2 processing is affected by M344 treatment. (A) S2-013 cells were
treated with 10 μM of M344 or equal volume of DMSO for the indicated times. Posttreatment, cell lysates were collected and immunoblotted for APLP2 (with an antibody
that also recognizes GAG-APLP2), APLP2-CT, and Hsc70 (loading control). The results
shown are representative of experiments performed on 3 separate cell lysates treated
with M344. (B) Densitometric analysis of APLP2-CT from the bands in A.

132

A.

B.

Done by Bailee Sliker and Dr. Ben Goetz

133
Further investigations into the question of whether BACE1 mediates this phenotype, or if
this is occurring by an alternate mechanism mediated by M344, are currently underway.

6.4 M344 and its effect on pancreatic cancer cell proliferation and migration

6.4.1 M344 treatment decreases pancreatic cancer cell proliferation but has no effect on
viability
The M344 drug has been shown to affect proliferation of the MCF-7 breast
cancer cell line by promoting apoptosis in these cells (Yeung et al., 2012). Therefore, to
assess the effect of M344 treatment on pancreatic cancer cells, both proliferation and
viability of the S2-103 cells were investigated. Using an MTT assay, it was found that at
all time points and all drug concentrations tested, there was a significant reduction in the
proliferation of S2-013 cells as compared to DMSO control (Figure 6.2A). In contrast,
studies of the effect of these same drug concentrations and treatment durations on S2013 cell viability showed that there was no change in cell viability, indicated by trypan
blue staining (Figure 6.2B).

6.3.2 M344 treatment decreases pancreatic cancer cell migration
To date, no published data has reported the effects of M344 on cell migration.
Pancreatic cancer is known for its ability to metastasize early and have high migratory
capabilities (Das and Batra 2015). Furthermore, APLP2 has been extensively implicated
in the regulation of cell migration and this extends to both APLP2-CT and GAG-APLP2
(Pandey et al., 2015). When S2-013 cells were treated with 10 μM M344, it was found
that the ability of these cells to migrate was significantly reduced (Figure 6.3A). This
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Figure 6.2. S2-013 pancreatic cancer cell proliferation is decreased upon M344
treatment but no change in cell viability is observed. (A) S2-013 cell proliferation after
treatment with various concentrations of M344 was assessed by MTT assay at the
indicated time points. Graphs are representative of optical density. The results are
representative from 2 separate experiments. Error bars represent the standard error of
the mean. Significance is set at *p<0.05, **p<0.01, ***p<0.001. (B) Viability of S2-013
cells was assessed by the trypan blue exclusion assay at 72 h post-treatment with
M344. Cells were treated with various concentrations of M344 and viability was graphed
as percentage of live cells. The results are representative from 4 separate experiments.
Error bars represent standard error of the mean. Significance is set at *p<0.05,
**p<0.01, ***p<0.001.
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was further supported by a decrease in the ability of the S2-013 cells to fully close the
scratch in a wound-healing assay (Figure 6.3B).

6.5 Discussion

HDAC inhibitors have been found to decrease cell proliferation and induce
apoptosis in a variety of different cancer types (Yeung et al., 2012). A recent study in a
model of Alzheimer’s disease indicated that an HDAC inhibitor, M344, decreases the
mRNA and protein expression of BACE1 (Volmar et al., 2017). BACE1 has been found
to be expressed in pancreatic cancer cells along with BACE2 (Figueroa et al., 2001). To
date, however, no one has investigated if alterations in BACE1 expression are seen
following M344 treatment of pancreatic cancer and if so, what happens to the processing
and subsequent cleavage of APLP2.
We found through these studies that in pancreatic cancer cells, M344 treatment
reduced proliferation, but has no overall effect on cell viability. Additionally, cell
migration and invasion were decreased as compared to the vehicle control (DMSO) after
M344 treatment. We further showed that M344 treatment at various time points induces
a reduction in APLP2-CT. Additionally, we unexpectedly observed a reduction in the
molecular weight of GAG-APLP2 upon treatment. As this modified form of APLP2 has
been implicated in affecting cell migration in CHO cells (Li et al., 1999), we expect that
some of the phenotypes that are observed have the potential to be caused by this
alteration as well.
BACE1 is also able to cleave APP, which is a family member of APLP2 (Walsh et
al., 2007). APP has been found to be expressed in pancreatic cancer cells, including
S2-013 cells, and has been previously indicated to affect cell proliferation in this disease
(Hansel et al., 2003; Peters et al., 2012; Venkataramani et al., 2010). Comprehension of
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Figure 6.3. Migration of pancreatic cancer cells is reduced upon treatment with the
HDAC inhibitor M344. (A) Transwell assay was performed to assess migration of S2013 cells. Cells were pre-treated with 10 μM of M344 or DMSO for 24 h. After
treatment, cells were plated into 8-μm inserts and incubated for 24 h. Inserts were fixed
and stained and photographs of 3 random fields were taken and the results were
averaged. Graphs show average numbers of cells that migrated. The results are
representative of 3 separate experiments. Error bars represent standard error of the
mean. Significance is set at *p<0.05, **p<0.01, ***p<0.001. (B) Scratch assays were
also performed to assess cell migration. S2-013 cells were pre-treated with 10 μM M344
or DMSO for 24 h. Using a 200 ul pipette tip, a scratch was made in the layer of cells
and non-drug containing media was replaced. Pictures were taken of the area at 8, 12,
and 26 hours after the scratch was made. The results are representative of 2 separate
experiments.
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the role that processing of APP may play in the observed phenotypes remains
incomplete. Additionally, BACE1 has the ability to cleave other targets (Kuhn et al.,
2007; Li and Sudhof 2004; Sugimoto et al., 2007). The role that these other targets of
BACE1 enzymatic activity may be playing in the changes observed in cell proliferation
and migration have not been investigated to date. Furthermore, the effects that the
additional proteins targeted by reduction in BACE1 enzymatic activity have on APLP2
processing (both C-terminal fragment formation and glycosaminoglycan modification)
remains unknown.
In total, these discoveries have elucidated that M344 has the ability to decrease
pancreatic cancer cell proliferation and migration, and our findings are consistent with
the mediation of these effects through M344 altering the processing of APLP2. As
alterations in APLP2 processing, we have noted reduction in the level of APLP2-CT as
well as diminution of the molecular weight of GAG-APLP2. Since pancreatic cancer still
has a bleak 5-year survival rate that is the lowest among major solid tumors (Siegel et
al., 2018), better treatments of this disease remain urgently needed. Studies such as
this one suggest a potential new use for M344 in the treatment of this lethal disease.
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CHAPTER 7: Summary and future directions
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7.1 Summary of Research

Human leukocyte antigen (HLA) class I molecules are the human form of major
histocompatibility complex (MHC) class I molecules. These molecules are composed of
three main components, a light chain (also termed β2m), heavy chain, and antigenic
peptide. The heavy chains of these molecules are encoded by three genetic loci that
encode for three different isotypes, an –A, -B, and –C isotype. A unique aspect of these
molecules is their high rate of polymorphism. This has led to thousands of individual
sequence variations within the heavy chain isotypes and these variations are termed
allotypes. The best-known role for these molecules is within the immune system where
they present endogenous antigenic peptides to cytotoxic CD8+ T cells. However, recent
research has indicated that these molecules and their components could be playing a
role outside of this known immune function. Studies in transplantation biology models
have indicated that HLA class I molecules can contribute to cell proliferation and
migration in smooth muscle and endothelial cells. Additionally, β2m has been found to
be highly expressed in some cancer types including breast, prostate, and renal cell
carcinoma and has been found to play a role in promoting migration of renal cell and oral
squamous cell carcinomas. However, no studies have been published thus far on
investigation of the roles that these molecules may be playing outside of their known
immune function in pancreatic cancer. Additionally, no research has been carried out on
the molecular activities that specific isotypes or allotypes of these molecules may have
in these non-immune functions. Therefore, based on the findings from these previous
studies, I sought to investigate the role of components of the HLA class I molecule in
pancreatic cancer cell migration. I hypothesized that the components of the HLA class I
molecule (β2m and the HLA heavy chains) will affect pancreatic cancer cell migration
and that this will be heavy chain isotype and allotype specific.
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Pancreatic cancer is known to metastasize early, and a majority of patients fall
within the category of having distant disease. Pancreatic cancer has the worst
prognosis of any major solid tumor, and those individuals with distant disease have an
even more dismal prognosis. Therefore, we first sought to investigate the role of the
light chain, β2m, in pancreatic cancer migration. Studies using a Peggy Sue
(ProteinSimple) Simple Western instrument showed that β2m is amply expressed in an
immortalized but not fully transformed cell line (hTERT-HPNE cells) as well as in a panel
of pancreatic cancer cell lines. When β2m was knocked down using β2m-specific siRNA
in this panel of cells, migration was assessed using transwell assay. It was found that
the hTERT-HPNE cells did not have any change in migration upon knockdown of β2m.
In the S2-013 and PANC-1 pancreatic cancer cell lines, when β2m expression was
knocked down, decreased migration was observed. Conversely, the MIA PaCa-2 cell
line increased migration when β2m expression was lost. To further investigate the
mechanism behind this, amyloid precursor like protein 2 (APLP2), a protein that our lab
has shown as pro-migratory in this disease, was investigated. Interactions between this
protein and HLA class I molecules in complex with β2m were investigated, and it was
found that in the S2-013 and PANC-1 cells there was an interaction, but this interaction
did not exist in the MIA PaCa-2 cells. Furthermore, there was no change in overall
APLP2 protein expression in the hTERT-HPNE cells upon β2m knockdown while there
was a decrease in APLP2 expression in both the S2-013 and PANC-1 cells. In the MIA
PaCa-2 cells, an increase in APLP2 protein expression was observed. The presence of
an interaction between HLA class I molecules and APLP2, as well as corresponding
changes to APLP2 protein expression upon β2m knockdown, all align with the observed
changes in cell migration, thus leading us to the conclusion that the effects β2m has on
pancreatic cancer cell migration are potentially mediated through APLP2.
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The influence of the HLA class I heavy chains on pancreatic cancer cell migration
was also investigated. Initial studies investigated the effects of HLA-B on pancreatic
cancer. HLA-B, similarly to β2m, was expressed in all pancreatic cancer cell lines tested,
as compared to the hTERT-HPNE cells. Using a pan-HLA-B specific siRNA, knockdown
of HLA-B was accomplished in S2-013, PANC-1, and MIA PaCa-2 cells and migration
was investigated. An increase in migration occurred in the S2-013 cells upon
knockdown of HLA-B, while a reduction in migration was observed in both the PANC-1
and MIA PaCa-2 cells there. Integrins have been found to interact with HLA class I
molecules in transplantation biology models and are also crucial to pancreatic cancer
cell migration. Therefore, upon knockdown of HLA-B, the expression of the components
of the heterodimer of ITGA2/ITGB1 were investigated. In the S2-013 cell line, there was
an increase in total protein expression of ITGB1 but no change in ITGA2. Surface
expression of both of these integrins increased in this cell line upon HLA-B knockdown.
Conversely, in the PANC-1 and MIA PaCa-2 cell line, total ITGB1 expression was
reduced following HLA-B knockdown. After HLA-B knockdown, ITGA2 in the PANC-1
cell line followed the same trend as S2-013 cells for total expression; however, MIA
PaCa-2 cells do not express ITGA2. Furthermore, the level of the downstream effector
FAK decreased (both total FAK and FAK phosphorylated at Y397) indicating that focal
adhesions are also being decreased upon HLA-B knockdown. Thus, both integrins and
FAK may be potential intermediates of HLA-B’s effect on pancreatic cancer cell
migration.
Effects of the HLA-A heavy chain and its allotypes were also investigated.
Initially, the expression of HLA-A in a panel of pancreatic cancer cell lines in comparison
to the hTERT-HPNE cells was confirmed. HLA class I molecules are sometimes downregulated in cancer as a form of immune escape; however, our results, as well as other
studies in breast, lung, and gastric cancer, show that HLA class I downregulation on
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cancer cells is often not evident. S2-013 cells express both the HLA-A2 and HLA-A24
allotypes, while PANC-1 cells have HLA-A2 and MIA PaCa-2 cells have HLA-A24. Each
of these specific allotypes was knocked down using siRNA specifically designed by our
lab to target these individual heavy chain allotypes, and knockdown efficiency ranged
from 50-99%. In the S2-013 cells, when HLA-A2 was knocked down, cell migration was
reduced, while knockdown of HLA-A24 in this same cell line greatly induced cell
migration. Conversely, however, the same allotypes in the other cell lines had the
opposite effects on migration. In the PANC-1 cell line, HLA-A2 knockdown led to a
corresponding boost in cell migration, whereas in the MIA PaCa-2 cell line HLA-A24
knockdown led to a decrease in cell migration. Mechanistic studies indicated that HLAA2 interacts with EGFR in PANC-1 cells and HLA-A2 knockdown induces an increase in
EGFR in this same cell line. Conversely, HLA-A2 in S2-013 cells did not interact with
EGFR and HLA-A2 knockdown reduced EGFR protein expression in this cell line.
Studies have determined that APLP2 knockout leads to an increase in EGFR expression
and current studies are underway to investigate a role for APLP2, EGFR, and the HLA-A
allotypes in affecting pancreatic cancer cell migration. Thus, it is speculated that EGFR
acts as a potential intermediate in the effects of HLA-A allotypes on pancreatic cancer
cell migration. Further studies delving deeper into the mechanisms mediating the effects
of HLA-A24 on pancreatic cancer cell migration are still ongoing.
The final studies that were conducted as part of this dissertation research include
investigation of the effects of the HDAC inhibitor M344 on APLP2 processing in
pancreatic cancer cells and on pancreatic cancer cell proliferation and migration.
Previous studies using M344 found that, in a model of Alzheimer’s disease, treatment
with this inhibitor reduced levels of the proteolytic enzyme BACE1. BACE1 is involved in
cleavage of the APP family of proteins, including APLP2, which is a protein found by our
lab to be highly expressed in pancreatic cancer cells. Previous studies from our lab
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have implicated a proteolytic fragment of APLP2 (APLP2-CT) in pancreatic cancer cell
migration and proliferation. Therefore, we sought to study the effects of M344 on
pancreatic cancer cell proliferation and migration through its influence on APLP2
processing. We found that M344 treatment led to a significant reduction in cell
proliferation, especially at 48 and 72 hours post-treatment. Similar results were seen
with cell invasion and migration, where treatment with M344 led to a reduction in the
ability of cells to migrate and invade, as demonstrated by the wound scratch assay and
transwell assay. Interestingly, there was no significant effect on cell viability in the S2013 cells after M344 treatment. Upon investigation into the effects of M344 on APLP2
expression, we detected no changes in the full-length form of APLP2, but we observed a
reduction in APLP2-CTF upon treatment with increasing concentrations of M344.
Unexpectedly, we also observed a downward shift in the molecular weight of the
chondroitin sulfate glycosaminoglycan modified form of APLP2 (GAG-APLP2), which
suggests that the structure of carbohydrate moiety. This modified form of APLP2 has
been previously implicated in cell migration. Mouse orthotopic xenograft transplantation
studies are currently underway to test the effects of M344 in comparison with a standard
of care treatment for pancreatic cancer (gemcitabine). Preliminary results indicate that
primary tumor growth is not affected much by this drug, but that the rates of metastatic
disease in the tumor-bearing mice is reduced compared with PBS control or gemcitabine
treatment. The overall results of this study point to M344 as a potential treatment for this
lethal disease, acting via effects on BACE1 as well as APLP2, and may lead to other
treatments targeting this axis.
In conclusion, this dissertation sought to investigate the overall role that
components of the HLA class I molecule have in the promotion of pancreatic cancer cell
migration, in conjunction with APLP2 and other proteins. We observed that β2m
promotes pancreatic cancer cell migration with APLP2 as a potential intermediary in this
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process. Additionally, we identified a novel role for the HLA class I molecules in
pancreatic cancer cell migration that was discovered to be allotype-specific. Overall,
these studies implicate HLA class I molecules, depending on the specific allotype, in the
promotion or reduction of migration (and therefore possibly metastasis) of pancreatic
cancer cells. This suggests that HLA class I molecules may be useful as prognostic
factors for this lethal disease in the future.

7.2 Investigate the effects of HLA class I molecules on pancreatic cancer cell
proliferation and viability

The aim of this section is to propose experiments to investigate further functional
roles that the HLA class I molecules may be playing in pancreatic cancer. Dysregulated
cell proliferation is also a hallmark of cancer, so investigating the role that HLA class I
molecules in regulating this process in pancreatic cancer is still needed. This
information has the potential to yield a greater understanding of the roles of these
molecules in cancer outside of their well-known immune function.

7.2.1 Previous studies on the effects of HLA class I molecules on cell proliferation and
viability
In addition to cell migration, HLA class I molecule components have been
implicated in affecting cell proliferation. Studies in transplantation biology models
showed that addition of a pan-HLA class I antibody induced cell proliferation (Jin et al.,
2002, Jin et al., 2005). In breast, prostate, and renal cell carcinoma models,
overexpression of the HLA class I light chain β2m also increased cancer cell proliferation
(Josson et al., 2011).
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7.2.2 Addition of a pan-HLA class I antibody reduces cell proliferation
To date, no studies have been published indicating if either β2m or specific
isotypes or allotypes of the HLA class I heavy chain affect pancreatic cancer cell
proliferation. Studies in transplantation biology have shown that treatment of endothelial
and smooth muscle cells with the W6/32 antibody (an antibody recognizing all HLA class
I heavy chains when in complex with β2m and peptide) induced cell proliferation, and
suggested that this was likely due to complex formation with growth factor receptors
such as FGFR on the cell surface (Jin et al., 2002; Jin et al., 2005). Additionally, studies
done in hematological malignancies indicated that treatment of these cells with a β2m
specific antibody led to a reduction in cell viability that only affected cancerous lesions
(Yang et al., 2006).
In our studies, S2-013 cells were treated were 10 ng/ml of azide-free W6/32
antibody. Azide has been previously described to affect cell viability (Ishikawa et al.,
2006; Slamenova and Gabelova 1980) so removal of this additional variable allowed for
proper investigation of HLA antibodies on cell proliferation. Contrary to what was
observed in transplantation biology models and hematological malignancy models,
antibody addition did not affect pancreatic cancer cell proliferation at any timepoint
tested (Figure 7.1)

7.2.3 Knockdown of the HLA-A heavy chain reduces cell proliferation but knockdown of
the HLA-B heavy chain has no effect on cell proliferation in a pancreatic cancer model
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Figure 7.1. No change in pancreatic cancer cell proliferation is observed upon treatment
with W6/32 antibody for 48 or 72 hours. S2-013 cells were treated with 10 ng/ml of
W6/32 or control IgG antibody for 48 or 72 hours. The control (“no treatment”) wells only
received an equivalent volume of 10% RPMI. Proliferation was evaluated by MTT
assay. Error bars indicate the standard error of the mean. The results are
representative of 3 separate MTT assays performed.
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Some studies have indicated that HLA-A affects PBMC cell proliferation and that
HLA-B knockdown leads to a decrease in cell proliferation in laryngeal carcinogenesis
(Guo et al., 2008; Taylor et al., 1986). To examine the influence of HLA-A on pancreatic
cancer cell proliferation, HLA-A heavy chain was knocked down in the S2-013 pancreatic
cancer cell line using pan-HLA-A specific siRNA and a reduction in cell proliferation (as
indicated by total cell count) was observed at nearly all timepoints. The one exception to
this was at 72 hours, which could be due to experimental error (Figure 7.2A). This
trend, however, was not observed when the HLA-B isotype was knocked down in S2013 pancreatic cancer cells (Figure 7.2B). Under these conditions, no change in cell
proliferation (as indicated by total cell count) was observed at any timepoint tested.
Knockdown of β2m (using β2m-specific siRNA) in the S2-013 cell line showed the same
trend as HLA-B knockdown, i.e. no change in cell proliferation (as indicated by total cell
count) was observed at any timepoint tested (Figure 7.2C).

7.2.4 Knockdown of β2m, HLA-A, or HLA-B has no effect on pancreatic cancer cell
viability
Previous studies in various cell types have indicated that, in addition to changes
in cell proliferation, reductions in cell viability occur upon knockdown of β2m, HLA-B
heavy chain, or HLA-A heavy chain (Jin et al., 2005). However, knockdown of any of the
above components in pancreatic cancer cells using siRNA specific to these proteins
failed to show changes in cell viability at any timepoint tested (Figure 7.3A-C). This was
seem also seen in the S2-013 pancreatic cancer cell line and in a panel of other
pancreatic cancer cell lines.
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Figure 7.2. HLA-A knockdown led to a reduction in cell proliferation while neither HLA-B
knockdown nor β2m had an effect. At the indicated time points post-transfection, cell
proliferation following HLA-A or HLA-B knockdown was assessed by tryan blue staining.
Live cells were counted and the outcomes were graphed. S2-013 cell proliferation postβ2m knockdown was assessed by MTT at the indicated time points post-transfection of
siRNA. The results are from one experiment each for HLA-A knockdown, HLA-B
knockdown, and β2m knockdown. Errors bars represent the standard error of the mean.
Significance is set at p<0.05; *p<0.05, **p<0.01, ***p<0.001.
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Figure 7.3. Knockdown of any component of the HLA class I molecule has no effect on
cell viability. Cell viability is assessed by trypan blue exclusion assay. Viability is
graphed as percentage of live cells in the total cell number. All of the results are
representative of 3 separate experiments. Errors bars represent standard error of the
mean. Significance is set at p<0.05; *p<0.05, **p<0.01, ***p<0.001.
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7.2.5 Discussion
S2-013 cells treated with W6/32 antibody (recognizing all HLA class I heavy
chains in complex with β2m) showed no alterations in cell proliferation, as was also the
case when the HLA-B heavy chain or the HLA light chain β2m was knocked down in this
cell line. Conversely, in cells with transient knockdown of HLA-A, there was a significant
reduction in S2-013 cell proliferation, at nearly all timepoints tested. Conclusions that
can be drawn from these studies are that the HLA-A isotype plays a role in pancreatic
cancer cell proliferation and that this is a function independent from HLA-B and β2m.
Future endeavors investigating the role of specific HLA-A allotypes in control of this
process should be considered. Additionally, the mechanism behind the effects of HLA-A
on S2-013 proliferation should also be analyzed.

7.3 Elucidate the roles of the HLA-B specific allotypes in pancreatic cancer cell
migration

7.3.1 Previous studies of HLA-B allotypes in cancer and cell migration
As shown in a previous chapter of this dissertation, specific allotypes of the HLAA heavy chain have differential effects on cell migration. The goal of the studies
described in this section was to determine how allotypes of the HLA-B heavy chain
contribute to pancreatic cancer cell migration. These studies ultimately have the goal of
further characterizing the role of specific allotypes of the HLA class I molecule heavy
chain play in promoting the migration of pancreatic cancer cells and potentially
metastasis in patients.
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7.3.2 Knockdown of HLA-B7 or HLA-B59 in S2-013 cells leads to a reduction in cell
migration
In S2-013 cells, specific siRNAs targeting the allotypes that exist in this cell line
(HLA-B7 and HLA-B59) were used to knock down each individual allotype. Knockdown
of HLA-B7 was confirmed using flow cytometry (Figure 7.4). HLA-B59 protein
knockdown confirmation is not currently technically feasible, due to the lack of a
commercially available antibody with the appropriate specificity. Knockdown of either
allotype resulted in a significant reduction in cell migration (Figure 7.5A-B). This
suggests, in context with the data on the pan-HLA-B siRNA knockdowns described in an
earlier chapter of this dissertation, that knockdown of each allotype alone reduces
migration, but reduction of both allotypes together could lead to the opposite phenotype.

7.3.3. Discussion
As indicated in a preceding chapter, S2-013 cells transfected with a pan-HLA-B
siRNA demonstrate faster migration. However, when each individual allotype is knocked
down separately, a reduction in migration rate is observed in both. These studies have
further illuminated the role of HLA class I allotypes, specifically HLA-B allotypes, in
pancreatic cancer cell migration. Additionally, these findings demonstrate that the
migratory phenotype can be changed if only one specific allotype versus both are
knocked down. Further confirmation of these trends in other pancreatic cancer cell lines
that express these particular allotypes is needed. Additionally, investigation of the
mechanisms that control these differences should also be conducted.
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Figure 7.4. HLA-B7 knockdown confirmation for S2-013 pancreatic cancer cells. Flow
cytometry was performed using an HLA-B7 antibody 72 h post-transfection with HLA-B7
or HLA-B59 specific siRNA. Scramble is control non-targeting siRNA. HLA-B7 was
robustly expressed in S2-013 cells as evidenced by staining in the scramble siRNAtransfected cells. HLA-B7 knockdown was confirmed in cells transfected with HLA-B7
siRNA. HLA-B59 siRNA has no observable effect on HLA-B7 expression and was
included as a control. The results are shown are from one experiment.
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Figure 7.5. Knockdown of either allotype of HLA-B in S2-013 cells leads to a reduction
in cell migration. (A) Transwell assays were used to determine cell migration 72 h posttransfection with HLA-B7-specific siRNA. S2-013 cells, at 72 h post-transfection, were
replated into 8-μm inserts and incubated for 24 h. Cells were stained and pictures were
taken of 3 random fields. Counts were averaged and graphed with error bars
representing the standard error of the mean. The results are representative of 5
separate experiments. Significance was set at p<0.05; *p<0.05, **p<0.01, ***p<0.001.
(B) Transwell assays were used to determine cell migration at 72 h post-transfection
with HLA-B7-specific siRNA. S2-013 cells, at 72 h post-transfection, were replated into
8-μm inserts and incubated for 24 h. Cells were stained and pictures were taken of 3
random fields. Counts were averaged and graphed with error bars representing the
standard error of the mean. The results are representative of 5 separate experiments.
Significance was set at p<0.05; *p<0.05, **p<0.01, ***p<0.001.
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7.4 Identify the functional relevance of the effects of TGF-β treatment on the
regulation of cell migration by HLA class I molecules

The goal of these studies was to investigate if TGF-β alters pancreatic cancer
cell migration when HLA class I heavy chain isotypes or allotypes are knocked down by
siRNA transfection. The results of these studies can provide further insight into crosstalk
between certain growth factor ligands and HLA class I molecules on pancreatic cancer
cell migration, and could ultimately provide additional targets for treatment of this lethal
disease.

7.4.1 Previous studies on TGF-β and HLA class I molecules
A previous report showed that treatment of prostate cancer cells with TGF-β can
induce changes in expression of HLA class I molecules. Specifically, HLA-B mRNA was
down-regulated, and the surface expression of this particular isotype was reduced (Chen
et al., 2015). However, no studies have thus far investigated the effects of TGF-β on
migration or proliferation in the context of knockdown of HLA class I molecules.

7.4.2 S2-013 cells in which HLA-B is knocked down and that have been treated with
TGF-β have a significant induction in migration
As mentioned in an earlier chapter of this dissertation, knockdown of the HLA-B
isotype in S2-013 cells leads to an increase in pancreatic cancer cell migration.
Interestingly, when S2-013 cells deficient in HLA-B are treated with TGF-β, the
increased migration phenotype is further enhanced. Upon TGF-β treatment, S2-013
cells transfected with control siRNA, showed a modest yet significant increase in cell
migration. However, when S2-013 cells were transfected with HLA-B siRNA, the
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increase in cell migration that was observed without treatment of TGF-β was elevated
even further when TGF-β was introduced into the medium (Figure 7.6).

7.4.3 Treatment with TGF-β alters expression of HLA-B in pancreatic cancer cells in
which HLA-A has been knocked down
The effect of TGF-β on heavy chain expression compensation was also
investigated in the S2-013 cells. Compensation between heavy chains does not usually
occur in the S2-013 cell line upon knockdown of one HLA class I isotype; however, when
S2-013 cells were treated with TGF-β after HLA-A knockdown, there was a robust
increase in the expression of HLA-B (as indicated by HC-10) (Figure 7.7).

7.4.4 Discussion
These data indicate that the expression of HLA class I molecules, specifically
HLA-B molecules in S2-013 pancreatic cancer cells, is highly responsive to TGF-β
treatment. The phenotype in S2-013 cells that was observed when HLA-B was knocked
down, i.e., that migration was facilitated, was further accentuated by TGF-β treatment.
Moreover, these data indicate that the presence of TGF-β in the tumor microenvironment
could lead to greater migration of pancreatic cancer cells, consistent with findings by
others that TGF-β increases pancreatic cancer cell migration (Witte et al., Oncology
Reports 2017). Therefore, these studies are relevant to a signaling pathway that may be
contributing to metastasis in this deadly disease.

7.5 Further determine the intersection of HLA class I molecules and integrins in
pancreatic cancer cell migration and proliferation
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Figure 7.6. TGF-β treatment further enhances the increase in pancreatic cancer cell
migration. S2-013 cells were treated with either maintenance media or with 10 ng/ml of
TGF-β at 24 h post-transfection. Treatment lasted for 48 h and then cells were plated for
transwell assay in 8-μm inserts and incubated for 24 h. Cells were fixed and stained and
photographed, taking 3 random fields. Averages were taken and graphed with error
bars indicating the standard error of the mean. The results are representative of 2
separate experiments. Significance is set at p<0.05; *p<0.05, **p<0.01, ***p<0.001.
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Figure 7.7. HLA-B expression was induced upon HLA-A knockdown when cells were
treated with TGF-β. S2-013 cells were treated with either maintenance media or
maintenance media with 10 ng/ml of TGF-β 24 h post-transfection with HLA-A-specific
siRNA. Treatment lasted for 48 h and then cell lysates were collected and
immunoblotted for HLA-B (with the HC-10 antibody). Hsc70 was used as a loading
control. The results shown are from one experiment.
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The aim of this section is to propose experiments to identify additional cancerrelated integrins with which HLA class I molecules interact in pancreatic cancer cells, as
well as to investigate if integrins have effects on HLA class I molecule expression.
Integrins contribute to many cancer-related processes such as proliferation and
migration (Bianconi et al., 2016). Thus, investigating the intersection between HLA class
I molecules and integrins in regulating these processes in pancreatic cancer thus is
relevant. This information has the potential to allow a greater understanding of the roles
of HLA class I molecules in cancer outside of immunological functions.

7.5.1 Previous studies on HLA class I and integrins
In addition to the integrin α2β1 heterodimer and EGFR, the cancer-associated
integrin beta 4 (ITGB4), was also previously investigated as interacting with HLA class I
molecules (Zhang et al., 2010). These studies conducted in transplantation biology
models indicated that HLA class I molecules and ITGB4 interact and that this interaction
can affect cell migration and proliferation (Zhang et al., 2010). No studies, however,
have investigated if this interaction exists in pancreatic cancer. Furthermore, even
though it was shown in an earlier chapter of this dissertation that HLA class I molecules
can interact with the α2β1 heterodimer, no studies have yet been reported that have
investigated if integrins affect HLA class I expression and if this alters pancreatic cancer
cell migration.

7.5.2 Certain isotypes of the HLA class I molecule heavy chains interact with ITGB4
ITGB4 is an integrin molecule that is over-expressed in a variety of cancers,
including pancreatic cancer, and that is involved in the motility of various types of cancer
cells (Cruz-Monserrate and O’Connor 2008; Masugi et al., 2015; Mercurio and
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Rabinovitz 2001). Our analysis of a panel of pancreatic cancer cell lines determined that
only S2-013 and BxPC3 cells express this integrin (data not shown). Coimmunopreciptation experiments for ITGB4 in these two cell lines identified an
association of ITGB4 with both HLA-A and HLA-B heavy chains in S2-013 cells (Figure
7.8). However, in the BxPC3 cells, only an association of ITGB4 with HLA-A was
observed, although this could be due to the relatively low expression of HLA-B in this cell
line (Figure 7.8).

7.5.3 Knockdown of certain integrins affects pancreatic cancer cell migration
Additionally, in a panel of pancreatic cancer cells, knockdown of various integrin
molecules was performed and the effects on cell migration were assessed by transwell
assay. In S2-013 cells, migration was found to be significantly increased when either
ITGB1 or ITGA2 was knocked down (Figure 7.9 and 7.10). In the PANC-1 pancreatic
cancer cell line, knockdown of ITGA2 had no effect on cell migration, while ITGB1
knockdown significantly reduced the migration rate (Figure 7.9 and 7.10). ITGB1
knockdown decreased cell migration to a similar extent In the MIA PaCa-2 cell line
(Figure 7.9). The MIA PaCa-2 cell line does not have ITGA2, as mentioned earlier in
this dissertation, so knockdown of ITGA2 could not be pursued in this cell line.

7.5.4 Knockdown of certain integrins affects HLA class I isotype overall protein
expression

Due to the interactions that exist between ITGA2 and ITGB1 with HLA class I
molecules (as mentioned earlier in this dissertation), as well as the effects that these
integrins have on cell migration, the changes in the expression levels of the HLA class I
heavy chain isotypes upon knockdown of ITGA2 and ITGB1 were also assessed. In
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Figure 7.8. ITGB4 associates with HLA class I molecules in pancreatic cancer cells.
Cell lysates were collected and an ITGB4 antibody was used for immunoprecipitations in
S2-013 and BxPC3 pancreatic cancer cell lines. Negative controls (an anti-rabbit IgG
antibody as well as an ITGB4 antibody with no cells) were also included.
Immunoblotting was then performed on the immunopreciptations, probing with
antibodies specific to HLA-A or HLA-B. Probing for ITGB4 was also done to confirm the
success of the ITGB4 immunopreciptation. The results shown are from one experiment
for both S2-013 and BxPC3.
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Figure 7.9. Knockdown of ITGB1 in pancreatic cancer cell lines affects cell migration.
Transwell assays were used to determine the migration at 72 h post-transfection of
ITGB1-specific siRNA-transfected pancreatic cancer cells. The cells, at 72 h posttransfection, were replated into 8-μm inserts and incubated for 24 h. Cells were stained
and pictures were taken of 3 random fields. The counts were averaged and graphed
with error bars indicating the standard error of the mean. The results are representative
of 2 separate experiments for S2-013 cells, 3 experiments for PANC-1 cells, and 2
experiments for MIA PaCa-2 cells. Significance is set at p<0.05; *p<0.05, **p<0.01,
***p<0.001.
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Figure 7.10. Knockdown of ITGA2 in pancreatic cancer cell lines alters cell migration.
Transwell assays were used to determine cell migration 72 h post-transfection with HLAB7-specific siRNA. The cells, at 72 h post-transfection, were replated into 8-μm inserts
and incubated for 24 h. Cells were stained and pictures were taken of 3 random fields.
The counts were averaged and graphed with error bars indicating the standard error of
the mean. The results are representative of 2 separate experiments for S2-013 cells
and 4 separate experiments for PANC-1 cells. Significance is set at p<0.05; *p<0.05,
**p<0.01, ***p<0.001.
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S2-013 cells, HLA-A and HLA-B protein expression levels were decreased if ITGB1 was
knocked down, but this did not occur in the case of ITGA2 knockdown (Figures 7.11A
and 7.12). Interestingly, no change in the expression level of either HLA class I heavy
chain has been observed thus far upon knockdown of either integrin molecule (ITGA2 or
ITGB1) in the PANC-1 cell line (Figures 7.11B and 7.12). Similarly, no change in either
HLA heavy chain isotype was observed in the MIA PaCa-2 cells upon ITGB1 knockdown
(Figure 7.11B).

7.5.5 Discussion
Integrins are important cell-surface molecules in many cancer-related processes
including proliferation, migration and angiogenesis (Bianconi et al., 2016). HLA class I
molecules have previously been found to interact with ITGB4 in transplantation biology
models and this interaction was found to contribute to cell proliferation and migration
(Zhang et al., 2010). However, whether a corresponding HLA class I/integrin
association, with similar effects, exists in pancreatic cancer has yet to be investigated.
These data encourage further studies into the role of HLA class I molecules in
conjunction with ITGB4 in pancreatic cancer. Additionally, these data support further
studies into how integrins may regulate pancreatic cancer cell migration through effects
on the expression of HLA class I molecules. This has implications not only for cell
migration, but also for normal immune recognition and for the efficacy of immunotherapy
approaches for pancreatic cancer. Further investigations into other integrins important in
pancreatic cancer such as ITGA3 and ITGA6 (Cruz-Monserrate and O’Connor 2008; Lee
et al., 2019; Masugi et al., 2015) would also be crucial to further this research.
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Figure 7.11. HLA class I heavy chain expression is altered in ITGB1-knockdown S2-013
cells but not in ITGB1-knockdown PANC-1 or MIA PaCa-2 cells. The pancreatic cancer
cell lines (A) S2-013 and (B) PANC-1 and MIA PaCa-2 were transfected with ITGB1specific siRNA or scramble control non-targeting siRNA. At 72 h post-transfection, cell
lysates were collected. Immunoblots were performed on the cell lysates investigating
the effects of ITGB1 knockdown on HLA-A and HLA-B protein expression. Hsc70 was
used as a loading control and ITGB1 knockdown was confirmed in these lysates by
probing with an anti-ITGB1 antibody. The results are representative of 2 separate
experiments for S2-013. For both PANC-1 and MIA PaCa-2 cells, results shown are
from one experiment.
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Figure 7.11. (B)
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Figure 7.12. HLA class I heavy chain expression is altered in ITGA2-knockdown S2-013
cells but not in ITGA2-knockdown PANC-1 cell. Cells were transfected with ITGA2specific siRNA or scramble control non-targeting siRNA. At 72 h post-transfection, cell
lysates were collected. Immunoblots were performed on cell lysates to investigate the
effects of ITGA2 knockdown on HLA-A and HLA-B expression. Hsc70 is used as a
loading control and ITGA2 knockdown was confirmed in these lysates by probing with an
ITGA2-specific antibody. The results are representative of 2 separate experiments for
S2-013. For PANC-1 cells, results shown are from one experiment.
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7.6 Investigate role of the Hippo pathway downstream of HLA class I molecules

Previous studies have reported an intersection between members of the Hippo
signaling pathway and integrins as well as TGF-β (Margadant and Sonnenberg 2010;
Xiang et al., 2018). Therefore, studies were initiated to investigate the role that the
Hippo signaling pathway plays downstream of HLA class I molecules, as other work
described in this dissertation has indicated that intersecting pathways involving integrins
and TGF-β are affected by HLA class I molecules. These studies could lead to further
knowledge about downstream signaling pathways that are affected by HLA class I
molecules and thus could lead to a greater repertoire of targets for treatment of this
devastating disease.

7.6.1 pYap and pLATS1 are differentially affected by HLA-A and HLA-B knockdown
In S2-013 cells, knockdown of HLA-A and HLA-B was achieved by transient
siRNA knockdown (data not shown). The expression of pYap S125 (i.e., the Hippo
pathway protein Yap phosphorylated at a common activation site of this molecule) was
assessed post-HLA heavy chain isotype knockdown. The pYap S125 level was found to
decrease when HLA-A was knocked down but increase when HLA-B was knocked down
(Figure 7.13). The effect of HLA-A and –B on the expression of the upstream Hippo
pathway molecule LATS1 was also investigated. The phosphorylation of LATS1 is
mediated by Mst1/2, which leads to activation of LATS1. Once activated, LATS1 can
phosphorylate Yap, which leads to its subsequent inactivation and degradation (Yu and
Guan 2013). Similarly, pLATS1 S909 was decreased in HLA-A knockdown and
increased in HLA-B knockdown cells (Figure 7.13).
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7.6.2 Discussion
The Hippo pathway is dysregulated in a variety of different cancers, including
pancreatic cancer (Rozengurt et al., 2018; Zanconato et al., 2016). The pathway
controls a variety of different cancer-related phenotypes such as cell proliferation,
progression through the cell cycle, and cell migration (Yang et al., 2015). To date, no
studies have implicated HLA class I molecules in modulation of the Hippo pathway in
any model, including cancer. The role of the Hippo pathway in immunology is an active
area of research, however, and further investigation into the role of HLA class I
molecules in the Hippo pathway, as well as its potential influence on HLA class I
expression, is warranted, and may contribute to the development of new molecular
therapeutics and immunotherapeutics for pancreatic cancer and other cancer types.
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Figure 7.13. Components of the Hippo pathway are differentially regulated by HLA-A
and HLA-B knockdown in S2-013 pancreatic cancer cells. S2-013 cells were transfected
with HLA-A, HLA-B, or control siRNA. At 72 h post-transfection cell lysates were
collected and immunoblotted for either pLATS1 S909, pYap S125, or Hsc70 (loading
control). The results are representative of 4 separate experiments for HLA-A knockdown
and 3 separate experiments for HLA-B knockdown.
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Figure 7.13.
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